DK2620428T3 - Asymmetrisk hjælpegruppe - Google Patents

Asymmetrisk hjælpegruppe

Info

Publication number: DK2620428T3
Authority: DK; Denmark
Prior art keywords: asymmetric; help group; help; group; asymmetric help
Prior art date: 2010-09-24

Application number

DK11826893.7T

Other languages

English (en)

Inventor

Takeshi Wada

Mamoru Shimizu

Original Assignee

Wave Life Sciences Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-24

Filing date

2011-09-22

Publication date

2019-07-01

2011-09-22 Application filed by Wave Life Sciences Ltd filed Critical Wave Life Sciences Ltd

2019-07-01 Application granted granted Critical

2019-07-01 Publication of DK2620428T3 publication Critical patent/DK2620428T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/62—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Saccharide Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)
Indole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK11826893.7T 2010-09-24 2011-09-22 Asymmetrisk hjælpegruppe DK2620428T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US38601610P	2010-09-24	2010-09-24
PCT/JP2011/071559 WO2012039448A1 (ja)	2010-09-24	2011-09-22	不斉補助基

Publications (1)

Publication Number	Publication Date
DK2620428T3 true DK2620428T3 (da)	2019-07-01

Family

ID=45873932

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK11826893.7T DK2620428T3 (da)	2010-09-24	2011-09-22	Asymmetrisk hjælpegruppe

Country Status (5)

Country	Link
US (1)	US10428019B2 (da)
EP (1)	EP2620428B1 (da)
JP (3)	JP5868324B2 (da)
DK (1)	DK2620428T3 (da)
WO (1)	WO2012039448A1 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG171914A1 (en)	2008-12-02	2011-07-28	Chiralgen Ltd	Method for the synthesis of phosphorus atom modified nucleic acids
WO2011005761A1 (en)	2009-07-06	2011-01-13	Ontorii, Inc	Novel nucleic acid prodrugs and methods use thereof
EP2620428B1 (en)	2010-09-24	2019-05-22	Wave Life Sciences Ltd.	Asymmetric auxiliary group
DK2734208T3 (da)	2011-07-19	2017-06-19	Wave Life Sciences Ltd	Fremgangsmåder til syntese af funktionaliserede nukleinsyrer
KR101835401B1 (ko)	2012-07-13	2018-03-08	신 니뽄 바이오메디칼 라보라토리즈, 엘티디.	키랄 핵산 어쥬번트
EP2872147B1 (en)	2012-07-13	2022-12-21	Wave Life Sciences Ltd.	Method for making chiral oligonucleotides
CN107011400B (zh)	2012-07-13	2021-05-25	波涛生命科学有限公司	不对称辅助基团
WO2015108047A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108046A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
JPWO2015108048A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
AU2015207773B2 (en)	2014-01-16	2021-06-17	Wave Life Sciences Ltd.	Chiral design
MA43072A (fr)	2015-07-22	2018-05-30	Wave Life Sciences Ltd	Compositions d'oligonucléotides et procédés associés
CA2999772A1 (en)	2015-10-09	2017-04-13	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods thereof
EP3430019A4 (en)	2016-03-13	2019-10-30	Wave Life Sciences Ltd.	COMPOSITIONS AND METHODS FOR PHOSPHORAMIDITE AND OLIGONUCLEOTIDE SYNTHESIS
MX2018012695A (es)	2016-04-18	2019-06-20	Sarepta Therapeutics Inc	Oligomeros antisentido y metodos de uso de los mismos para tratar enfermedades relacionadas con el gen alpha-glucosidasa acido.
EP3449000A1 (en)	2016-04-29	2019-03-06	Sarepta Therapeutics, Inc.	Oligonucleotide analogues targeting human lmna
MA45270A (fr)	2016-05-04	2017-11-09	Wave Life Sciences Ltd	Compositions d'oligonucléotides et procédés associés
EP3458464A1 (en)	2016-05-18	2019-03-27	ETH Zurich	Stereoselective synthesis of phosphorothioate oligoribonucleotides
MA45188A (fr)	2016-06-03	2019-04-10	Wave Life Sciences Ltd	Oligonucléotides, compositions et méthodes associées
MA45618A (fr)	2016-06-30	2019-05-08	Sarepta Therapeutics Inc	Sauts d'exons oligomères pour la dystrophie musculaire
CN110088113A (zh)	2016-11-23	2019-08-02	波涛生命科学有限公司	用于亚磷酰胺和寡核苷酸合成的组合物和方法
HRP20240705T1 (hr)	2016-12-19	2024-08-30	Sarepta Therapeutics, Inc.	Oligomerni konjugati koji preskaču egzon za mišićnu distrofiju
DK3554553T3 (da)	2016-12-19	2022-09-19	Sarepta Therapeutics Inc	Exon-overspringnings-oligomerkonjugat til muskeldystrofi
WO2018118662A1 (en)	2016-12-19	2018-06-28	Sarepta Therapeutics, Inc.	Exon skipping oligomer conjugates for muscular dystrophy
CN110475784B (zh) *	2017-03-29	2024-07-16	罗氏创新中心哥本哈根有限公司	用于制备立体限定硫代磷酸酯寡核苷酸的正交保护基
CN111050806A (zh)	2017-06-02	2020-04-21	波涛生命科学有限公司	寡核苷酸组合物及其使用方法
WO2018223081A1 (en)	2017-06-02	2018-12-06	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods of use thereof
US11718638B2 (en)	2017-06-21	2023-08-08	Wave Life Sciences Ltd.	Compounds, compositions and methods for synthesis
SG11202000274RA (en)	2017-08-08	2020-02-27	Wave Life Sciences Ltd	Oligonucleotide compositions and methods thereof
EP3684755A4 (en)	2017-09-18	2022-03-02	Wave Life Sciences Ltd.	OLIGONUCLEOTIDE PREPARATION TECHNOLOGIES
EA201991450A1 (ru)	2017-09-22	2019-12-30	Сарепта Терапьютикс, Инк.	Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
JP2020536057A (ja)	2017-09-28	2020-12-10	サレプタセラピューティクス，インコーポレイテッド	筋ジストロフィーを処置するための併用療法
WO2019067981A1 (en)	2017-09-28	2019-04-04	Sarepta Therapeutics, Inc.	POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
EP3687547A1 (en)	2017-09-28	2020-08-05	Sarepta Therapeutics, Inc.	Combination therapies for treating muscular dystrophy
EP3694530A4 (en)	2017-10-12	2021-06-30	Wave Life Sciences Ltd.	OLIGONUCLEOTIDE COMPOSITIONS AND METHOD FOR THEREFORE
EP3697910A4 (en)	2017-10-18	2021-07-14	Sarepta Therapeutics, Inc.	ANTISENSE OLIGOMERIC COMPOUNDS
US10765760B2 (en)	2018-05-29	2020-09-08	Sarepta Therapeutics, Inc.	Exon skipping oligomer conjugates for muscular dystrophy
EP3806868A4 (en)	2018-06-13	2022-06-22	Sarepta Therapeutics, Inc.	EXON-SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
TW202020153A (zh)	2018-07-27	2020-06-01	美商薩羅塔治療公司	用於肌肉萎縮症之外顯子跳躍寡聚物
CA3122281A1 (en)	2018-12-13	2020-06-18	Sarepta Therapeutics, Inc.	Exon skipping oligomer conjugates for muscular dystrophy
US20230089442A1 (en) *	2019-03-20	2023-03-23	Pachamuthu Kandasamy	Technologies useful for oligonucleotide preparation
WO2020214763A1 (en)	2019-04-18	2020-10-22	Sarepta Therapeutics, Inc.	Compositions for treating muscular dystrophy
MX2024003690A (es)	2021-09-30	2024-06-19	Sarepta Therapeutics Inc	Oligonucleótidos antisentido que tienen una o más unidades abásicas.
WO2024064237A2 (en)	2022-09-21	2024-03-28	Sarepta Therapeutics, Inc.	Dmd antisense oligonucleotide-mediated exon skipping efficiency
US20250066776A1 (en)	2023-04-27	2025-02-27	Sarepta Therapeutics, Inc.	Antisense oligomers for treatment of chronic kidney disease

Family Cites Families (685)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE133885C (da)
US2878264A (en) *		1959-03-17		Substituted amino alcohols
CH372667A (de) *	1957-09-26	1963-10-31	Robins Co Inc A H	Verfahren zur Herstellung von 3-Aryl-3-pyrrolidinolen
US3135766A (en)	1961-10-03	1964-06-02	Mead Johnson & Co	3-substituted-3-pyrrolidinols
US3484473A (en)	1967-05-12	1969-12-16	Buckman Labor Inc	Methylene bisesters of thiolsulfonic acids
DE1934150A1 (de)	1968-07-10	1970-01-15	Pennwalt Corp	Neue 1-Alkanoyloxy-1,2,4,5-tetrahydro-3H,3-benzazepine
US3687808A (en)	1969-08-14	1972-08-29	Univ Leland Stanford Junior	Synthetic polynucleotides
US3745162A (en) *	1970-08-31	1973-07-10	Robins Co Inc A H	1,2,3,4-tetrahydroisoquinoline-2-(thio)-carboxamides
GB1448437A (en)	1973-02-24	1976-09-08	Beecham Group Ltd	Diphenylpropylamines
US4022791A (en) *	1975-06-03	1977-05-10	Pfizer Inc.	2-Aminomethyl-3,4-dihydronaphthalenes
GB1504424A (en)	1975-08-09	1978-03-22	Beecham Group Ltd	Isoquinoline-derived aminoethers
BR7807288A (pt)	1977-11-08	1979-06-12	Genentech Inc	Processo para sintese de polinucleotidos
DD133885B1 (de)	1978-01-04	1981-02-25	Hans Lehmann	Mittel zur bekaempfung von phytopathogenen bakterien und pilzen
US4500707A (en)	1980-02-29	1985-02-19	University Patents, Inc.	Nucleosides useful in the preparation of polynucleotides
US5132418A (en)	1980-02-29	1992-07-21	University Patents, Inc.	Process for preparing polynucleotides
US4458066A (en)	1980-02-29	1984-07-03	University Patents, Inc.	Process for preparing polynucleotides
US4415732A (en)	1981-03-27	1983-11-15	University Patents, Inc.	Phosphoramidite compounds and processes
US4668777A (en)	1981-03-27	1987-05-26	University Patents, Inc.	Phosphoramidite nucleoside compounds
US4973679A (en)	1981-03-27	1990-11-27	University Patents, Inc.	Process for oligonucleo tide synthesis using phosphormidite intermediates
US4542142A (en)	1982-11-22	1985-09-17	Roussel Uclaf	Insecticidal cyclopropane carboxylic acid derivatives with 3-unsaturated-side chain
DE3329892A1 (de)	1983-08-18	1985-03-07	Köster, Hubert, Prof. Dr., 2000 Hamburg	Verfahren zur herstellung von oligonucleotiden
US5118800A (en)	1983-12-20	1992-06-02	California Institute Of Technology	Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5643889A (en)	1984-07-11	1997-07-01	Temple University-Of The Commonwealth System Of Pennsylvania	Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
FR2567892B1 (fr)	1984-07-19	1989-02-17	Centre Nat Rech Scient	Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5367066A (en)	1984-10-16	1994-11-22	Chiron Corporation	Oligonucleotides with selectably cleavable and/or abasic sites
FR2575751B1 (fr)	1985-01-08	1987-04-03	Pasteur Institut	Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
FR2576898B1 (fr)	1985-02-01	1988-01-08	Lafon Labor	Derives de 3-phenyl-tetrahydropyridine, procede de preparation et utilisation en therapeutique
US4659774A (en)	1985-11-01	1987-04-21	American Hoechst Corporation	Support for solid-phase oligonucleotide synthesis
US4840956A (en) *	1986-02-18	1989-06-20	Warner-Lambert Company	Novel disubstituted-7-pyrrolidinoquinoline antibacterial agents
US4735949A (en) *	1986-02-18	1988-04-05	Warner-Lambert Company	Disubstituted-7-pyrrolidinonaphthyridine antibacterial agents
IL83663A0 (en)	1986-10-27	1988-01-31	Robins Co Inc A H	Preparation of 3-pyrrolidinols
JP2828642B2 (ja)	1987-06-24	1998-11-25	ハワードフローレイインスティテュトオブイクスペリメンタルフィジオロジーアンドメディシン	ヌクレオシド誘導体
EP0302349B1 (en)	1987-07-30	1993-09-29	Bar Ilan University	Biologically active carboxylic acid esters
US4923901A (en)	1987-09-04	1990-05-08	Millipore Corporation	Membranes with bound oligonucleotides and peptides
US5175273A (en)	1988-07-01	1992-12-29	Genentech, Inc.	Nucleic acid intercalating agents
US4945158A (en)	1988-08-12	1990-07-31	American Cyanamid Company	Antidiabetic phosphonates
US4943629A (en)	1988-08-12	1990-07-24	American Cyanamid Company	Antidiabetic alpha-substituted phosphonates
US5047524A (en)	1988-12-21	1991-09-10	Applied Biosystems, Inc.	Automated system for polynucleotide synthesis and purification
US5262530A (en)	1988-12-21	1993-11-16	Applied Biosystems, Inc.	Automated system for polynucleotide synthesis and purification
JP2794461B2 (ja)	1989-08-17	1998-09-03	有機合成薬品工業株式会社	ホスホアミダイト化合物及びそれを用いたオリゴリボヌクレオチドの固相合成法
US5141813A (en)	1989-08-28	1992-08-25	Clontech Laboratories, Inc.	Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis
US5134066A (en)	1989-08-29	1992-07-28	Monsanto Company	Improved probes using nucleosides containing 3-dezauracil analogs
CA2029273A1 (en)	1989-12-04	1991-06-05	Christine L. Brakel	Modified nucleotide compounds
WO1991009594A1 (en) *	1989-12-28	1991-07-11	Virginia Commonwealth University	Sigma receptor ligands and the use thereof
US5130302A (en)	1989-12-20	1992-07-14	Boron Bilogicals, Inc.	Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5459255A (en)	1990-01-11	1995-10-17	Isis Pharmaceuticals, Inc.	N-2 substituted purines
US5506212A (en)	1990-01-11	1996-04-09	Isis Pharmaceuticals, Inc.	Oligonucleotides with substantially chirally pure phosphorothioate linkages
US5620963A (en)	1991-10-15	1997-04-15	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US5212295A (en)	1990-01-11	1993-05-18	Isis Pharmaceuticals	Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5646265A (en)	1990-01-11	1997-07-08	Isis Pharmceuticals, Inc.	Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5635488A (en)	1991-10-15	1997-06-03	Isis Pharmaceuticals, Inc.	Compounds having phosphorodithioate linkages of high chiral purity
US5852188A (en)	1990-01-11	1998-12-22	Isis Pharmaceuticals, Inc.	Oligonucleotides having chiral phosphorus linkages
US7101993B1 (en)	1990-01-11	2006-09-05	Isis Pharmaceuticals, Inc.	Oligonucleotides containing 2′-O-modified purines
US5457191A (en)	1990-01-11	1995-10-10	Isis Pharmaceuticals, Inc.	3-deazapurines
US6339066B1 (en)	1990-01-11	2002-01-15	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US5587470A (en)	1990-01-11	1996-12-24	Isis Pharmaceuticals, Inc.	3-deazapurines
JP2580091B2 (ja)	1990-01-11	1997-02-12	アイシス・ファーマシューティカルス・インコーポレーテッド	Ｒｎａ活性および遺伝子発現を検出および変調するための組成物および方法
US5587361A (en)	1991-10-15	1996-12-24	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5914396A (en)	1990-01-11	1999-06-22	Isis Pharmaceuticals, Inc.	2'-O-modified nucleosides and phosphoramidites
US5681941A (en)	1990-01-11	1997-10-28	Isis Pharmaceuticals, Inc.	Substituted purines and oligonucleotide cross-linking
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
US5292875A (en)	1990-04-20	1994-03-08	Lynx Therapeutics, Inc.	Method of synthesizing sulfurized oligonucleotide analogs
ATE186464T1 (de)	1990-05-23	1999-11-15	Isis Pharmaceuticals Inc	Zusammensetzungen und verfahren zur regulierung der rns-aktivität durch abänderung der rns ''5'- cap-struktur''
US5378825A (en)	1990-07-27	1995-01-03	Isis Pharmaceuticals, Inc.	Backbone modified oligonucleotide analogs
US5138045A (en)	1990-07-27	1992-08-11	Isis Pharmaceuticals	Polyamine conjugated oligonucleotides
US5783682A (en)	1990-07-27	1998-07-21	Isis Pharmaceuticals, Inc.	Oligonucleotide mimics having nitrogen-containing linkages
US5489677A (en)	1990-07-27	1996-02-06	Isis Pharmaceuticals, Inc.	Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5618704A (en)	1990-07-27	1997-04-08	Isis Pharmacueticals, Inc.	Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
US5608046A (en)	1990-07-27	1997-03-04	Isis Pharmaceuticals, Inc.	Conjugated 4'-desmethyl nucleoside analog compounds
US5223618A (en)	1990-08-13	1993-06-29	Isis Pharmaceuticals, Inc.	4'-desmethyl nucleoside analog compounds
US5677437A (en)	1990-07-27	1997-10-14	Isis Pharmaceuticals, Inc.	Heteroatomic oligonucleoside linkages
US5998603A (en)	1994-09-29	1999-12-07	Isis Pharmaceuticals, Inc.	4'-desmethyl nucleoside analogs, and oligomers thereof
CA2088258C (en)	1990-07-27	2004-09-14	Phillip Dan Cook	Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5792844A (en)	1990-07-27	1998-08-11	Isis Pharmaceuticals, Inc.	Oligonucleoside linkages containing adjacent nitrogen atoms
US5602240A (en)	1990-07-27	1997-02-11	Ciba Geigy Ag.	Backbone modified oligonucleotide analogs
US5688941A (en)	1990-07-27	1997-11-18	Isis Pharmaceuticals, Inc.	Methods of making conjugated 4' desmethyl nucleoside analog compounds
WO1994022886A1 (en)	1993-03-30	1994-10-13	Isis Pharmaceuticals, Inc.	Heteroatomic oligonucleoside linkages
US5541307A (en)	1990-07-27	1996-07-30	Isis Pharmaceuticals, Inc.	Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5834607A (en)	1990-07-27	1998-11-10	Isis Pharmaceuticals, Inc.	Amines and methods of making and using the same
US5623070A (en)	1990-07-27	1997-04-22	Isis Pharmaceuticals, Inc.	Heteroatomic oligonucleoside linkages
US6121433A (en)	1990-07-27	2000-09-19	Isis Pharmaceuticals, Inc.	Oligomeric compounds having nitrogen-containing linkages
US6087482A (en)	1990-07-27	2000-07-11	Isis Pharmaceuticals, Inc.	Heteroatomic oligonucleoside linkages
US5386023A (en)	1990-07-27	1995-01-31	Isis Pharmaceuticals	Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5610289A (en)	1990-07-27	1997-03-11	Isis Pharmaceuticals, Inc.	Backbone modified oligonucleotide analogues
US5432272A (en)	1990-10-09	1995-07-11	Benner; Steven A.	Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5512668A (en)	1991-03-06	1996-04-30	Polish Academy Of Sciences	Solid phase oligonucleotide synthesis using phospholane intermediates
US7015315B1 (en)	1991-12-24	2006-03-21	Isis Pharmaceuticals, Inc.	Gapped oligonucleotides
US20020183502A1 (en)	1991-05-21	2002-12-05	Mesmaeker Alain De	Backbone-modified oligonucleotide analogs and methods for using same
JPH04348077A (ja)	1991-05-24	1992-12-03	Nec Corp	薄膜トランジスタ
US6414112B1 (en)	1991-05-24	2002-07-02	Ole Buchardt	Peptide nucleic acids having 2,6-diaminopurine nucleobases
JPH06508024A (ja)	1991-06-10	1994-09-14	ラッキー・リミテッド	Ｃ型肝炎診断試薬およびワクチン
US5646267A (en)	1991-08-05	1997-07-08	Polish Academy Of Sciences	Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues
US5359052A (en)	1991-08-05	1994-10-25	Polish Academy Of Sciences	Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
US6369209B1 (en)	1999-05-03	2002-04-09	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US7119184B2 (en)	1991-08-12	2006-10-10	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US5607923A (en)	1991-10-15	1997-03-04	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
US5599797A (en)	1991-10-15	1997-02-04	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5576302A (en)	1991-10-15	1996-11-19	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
US5654284A (en)	1991-10-15	1997-08-05	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
US5661134A (en)	1991-10-15	1997-08-26	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
JP2693643B2 (ja)	1991-10-15	1997-12-24	アイシス・ファーマシューティカルス・インコーポレーテッド	キラルリン結合を有するオリゴヌクレオチド
ES2103918T3 (es)	1991-10-17	1997-10-01	Ciba Geigy Ag	Nucleosidos biciclicos, oligonucleotidos, procedimiento para su obtencion y productos intermedios.
US5594121A (en)	1991-11-07	1997-01-14	Gilead Sciences, Inc.	Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en)	1991-11-26	1996-01-16	Gilead Sciences, Inc.	Oligonucleotides containing 5-propynyl pyrimidines
US6235887B1 (en)	1991-11-26	2001-05-22	Isis Pharmaceuticals, Inc.	Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5359044A (en)	1991-12-13	1994-10-25	Isis Pharmaceuticals	Cyclobutyl oligonucleotide surrogates
EP1695979B1 (en)	1991-12-24	2011-07-06	Isis Pharmaceuticals, Inc.	Gapped modified oligonucleotides
GB9213601D0 (en)	1992-06-26	1992-08-12	Mastico Robert A	Protein based delivery system
US7067497B2 (en)	1992-09-29	2006-06-27	Isis Pharmaceuticals, Inc.	Modulation of telomere length by oligonucleotides having a G-core sequence
US6444656B1 (en)	1992-12-23	2002-09-03	Biochem Pharma, Inc.	Antiviral phosphonate nucleotides
US6005107A (en)	1992-12-23	1999-12-21	Biochem Pharma, Inc.	Antiviral compounds
ES2086997T3 (es)	1993-01-25	1996-07-01	Hybridon Inc	Oligonucleotido-alquilfosfonatos y -alquilfosfonotioatos.
JPH08508490A (ja)	1993-03-31	1996-09-10	スターリングウィンスロップインコーポレイティド	新規５’−置換ヌクレオシド及びそれから得られるオリゴマー
AU6551094A (en)	1993-03-31	1994-10-24	Sterling Winthrop Inc.	Bifunctional nucleosides, oligomers thereof, and methods of making and using the same
US5955591A (en)	1993-05-12	1999-09-21	Imbach; Jean-Louis	Phosphotriester oligonucleotides, amidites and method of preparation
US6015886A (en)	1993-05-24	2000-01-18	Chemgenes Corporation	Oligonucleotide phosphate esters
EP0628394B1 (en)	1993-06-10	1998-08-26	Idemitsu Petrochemical Co. Ltd.	Injection molding die
US5502177A (en)	1993-09-17	1996-03-26	Gilead Sciences, Inc.	Pyrimidine derivatives for labeled binding partners
US5643989A (en)	1993-10-29	1997-07-01	Azdel, Inc.	Fiber reinforced functionalized polyolefin composites
US5457187A (en)	1993-12-08	1995-10-10	Board Of Regents University Of Nebraska	Oligonucleotides containing 5-fluorouracil
DE4435728A1 (de)	1994-01-19	1995-07-20	Boehringer Mannheim Gmbh	Biotinsilan-Verbindungen und diese Verbindungen enthaltende Bindematrix
US6117679A (en)	1994-02-17	2000-09-12	Maxygen, Inc.	Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
EP0746618B1 (en)	1994-02-22	2002-08-21	Novozymes A/S	A method of preparing a variant of a lipolytic enzyme
US5596091A (en)	1994-03-18	1997-01-21	The Regents Of The University Of California	Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
RU2215034C2 (ru)	1994-05-11	2003-10-27	Новосимс А/С	ФЕРМЕНТ С АКТИВНОСТЬЮ ЭНДО-1,3(4)-β-ГЛЮКАНАЗЫ, КОДИРУЮЩАЯ ЕГО ДНК И СПОСОБ ЕГО ПОЛУЧЕНИЯ
US5525711A (en)	1994-05-18	1996-06-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Pteridine nucleotide analogs as fluorescent DNA probes
ES2127966T3 (es)	1994-05-31	1999-05-01	Bayer Ag	Derivados de amino-benzofurilo y -benzotienilo.
HRP950288A2 (en)	1994-05-31	1997-08-31	Bayer Ag	Oxalylamino-benzofuran- and benzothienyl-derivatives
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
DE69535905D1 (de)	1994-07-15	2009-02-26	Coley Pharm Group Inc	Immunomodulatorische Oligonukleotide
ATE202569T1 (de)	1994-09-07	2001-07-15	Hybridon Inc	Prodrug-oligonukleotide
US5681940A (en)	1994-11-02	1997-10-28	Icn Pharmaceuticals	Sugar modified nucleosides and oligonucleotides
WO1996019572A1 (en)	1994-12-22	1996-06-27	Hybridon, Inc.	Synthesis of stereospecific oligonucleotide phosphorothioates
GB9501465D0 (en)	1995-01-25	1995-03-15	King S College London	Nucleoside phosphorothioate derivatives,synthesis and use thereof
AU5359496A (en)	1995-03-06	1996-09-23	Isis Pharmaceuticals, Inc.	Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en)	1995-03-06	2000-12-26	Isis Pharmaceuticals, Inc.	Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
EP0739983B1 (en)	1995-04-27	2009-12-30	Takara Bio Inc.	Gene encoding lacto-n-biosidase
KR100449677B1 (ko)	1995-05-11	2004-11-20	어플라이드 리서치 시스템스	Il－6 활성 저해 물질
WO1996036627A1 (en)	1995-05-19	1996-11-21	Glycomed Incorporated	Collection of activated glycoside compounds and their biological use
AU5871196A (en)	1995-05-23	1996-12-24	Hybridon, Inc.	Methods and compounds for the synthesis of oligonucleotides and the oligonucleotides thereby produced
DK0836612T3 (da)	1995-05-23	2000-10-30	Hybridon Inc	Nye synthoner til stereoselektiv oligonucleotidsyntese
AU698739B2 (en)	1995-06-06	1998-11-05	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5932450A (en)	1995-06-07	1999-08-03	Gen-Probe Incorporated	Enzymatic synthesis of oligonucleotides using digestible templates
EP0759470B1 (en)	1995-06-29	2006-10-25	Takara Bio Inc.	Gene encoding endoglycoceramidase activator
EP0751222B1 (en)	1995-06-29	2006-03-01	Takara Bio Inc.	Gene encoding endoglycoceramidase
US6017700A (en)	1995-08-04	2000-01-25	Bayer Corporation	Cationic oligonucleotides, and related methods of synthesis and use
US5936080A (en)	1996-05-24	1999-08-10	Genta Incorporated	Compositions and methods for the synthesis of organophosphorus derivatives
WO1997009443A1 (en)	1995-09-05	1997-03-13	Michigan State University	PROCESS FOR THE ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM TAXUS spp
US6160109A (en)	1995-10-20	2000-12-12	Isis Pharmaceuticals, Inc.	Preparation of phosphorothioate and boranophosphate oligomers
US5734041A (en)	1995-10-20	1998-03-31	Mcgill University	Preparation of chiral phosphorothioate oligomers
US6476216B1 (en)	1995-10-20	2002-11-05	Mcgill University	Preparation of phosphorothioate oligomers
US7018793B1 (en)	1995-12-07	2006-03-28	Diversa Corporation	Combinatorial screening of mixed populations of organisms
US6214805B1 (en)	1996-02-15	2001-04-10	The United States Of America As Represented By The Department Of Health And Human Services	RNase L activators and antisense oligonucleotides effective to treat RSV infections
CN1215994A (zh)	1996-02-15	1999-05-05	国家健康学会	对治疗rsv感染有效的rna酶l激活剂和反义寡核苷酸
GB9604669D0 (en)	1996-03-05	1996-05-01	Ciba Geigy Ag	Chemical compounds
US5824669A (en)	1996-03-22	1998-10-20	Nitromed, Inc.	Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
DE69738254T2 (de)	1996-05-10	2008-08-14	Novozymes A/S	Methode zur bereitstellung von dna sequenzen
US5856465A (en)	1996-05-24	1999-01-05	Polska Akademia Nauk Centrum Badan Molekularnych I Makromolekularnych	Compositions and methods for the synthesis of chirally pure organophosphorus nucleoside derivatives
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
DE19622783A1 (de)	1996-06-07	1997-12-11	Hoechst Ag	Isolierung der Biosynthesegene für Pseudo-Oligosaccharide aus Streptomyces glaucescens GLA.O und ihre Verwendung
ES2270467T3 (es)	1996-07-16	2007-04-01	Gen-Probe Incorporated	Metodos para detectar y amplificar secuencias de acido nucleico utilizando oligonucleotidos modificados que tienen una tm especifica de la diana mas elevada.
CA2261566A1 (en)	1996-07-24	1998-01-29	Buchardt, Dorte	Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
WO1998007734A1 (en)	1996-08-21	1998-02-26	Hybridon, Inc.	Oligonucleotide prodrugs
US6056973A (en)	1996-10-11	2000-05-02	Sequus Pharmaceuticals, Inc.	Therapeutic liposome composition and method of preparation
GB9621522D0 (en)	1996-10-16	1996-12-04	Biocompatibles Ltd	Synthesis of phosphorus compounds
US6639062B2 (en)	1997-02-14	2003-10-28	Isis Pharmaceuticals, Inc.	Aminooxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
US6172209B1 (en)	1997-02-14	2001-01-09	Isis Pharmaceuticals Inc.	Aminooxy-modified oligonucleotides and methods for making same
US6369237B1 (en)	1997-03-07	2002-04-09	President And Fellows Of Harvard College	DNA glycosylase inhibitors, and uses related thereto
US6015887A (en)	1997-04-11	2000-01-18	Isis Pharmaceuticals, Inc.	Chiral peptide nucleic acids and methods for preparing same
US6468983B2 (en)	1997-04-21	2002-10-22	The Cleveland Clinic Foundation	RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
PL184612B1 (pl)	1997-04-25	2002-11-29	Pan	Sposób wytwarzania modyfikowanych P chiralnych analogów nukleotydów
NZ501289A (en)	1997-05-28	2001-06-29	Nielsen Peter E	Conjugated peptide nucleic acids having enhanced cellular uptake
CA2295110A1 (en)	1997-06-27	1999-01-07	The Procter & Gamble Company	Pro-fragrance cyclic acetals
WO1999005160A2 (en)	1997-07-25	1999-02-04	Hybridon, Inc.	Oligonuclotides having 3' terminal stereospecific phosphorothioates
US6767739B2 (en)	2001-07-30	2004-07-27	Isis Pharmaceuticals Inc.	Antisense modulation of microsomal triglyceride transfer protein expression
GB9717158D0 (en)	1997-08-13	1997-10-22	King S College London	Solution synthesis of oligonucleotides and their phosphorothioate analogues
US6383808B1 (en)	2000-09-11	2002-05-07	Isis Pharmaceuticals, Inc.	Antisense inhibition of clusterin expression
US6750344B1 (en)	1997-09-05	2004-06-15	Isis Pharmaceuticals, Inc.	Amine compounds and combinatorial libraries comprising same
US6794499B2 (en)	1997-09-12	2004-09-21	Exiqon A/S	Oligonucleotide analogues
DE19741715A1 (de)	1997-09-22	1999-03-25	Hoechst Ag	Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung
US6232463B1 (en)	1997-10-09	2001-05-15	Isis Pharmaceuticals, Inc.	Substituted purines and oligonucleotide cross-linking
US6528640B1 (en)	1997-11-05	2003-03-04	Ribozyme Pharmaceuticals, Incorporated	Synthetic ribonucleic acids with RNAse activity
US6617438B1 (en)	1997-11-05	2003-09-09	Sirna Therapeutics, Inc.	Oligoribonucleotides with enzymatic activity
US6080543A (en)	1997-12-08	2000-06-27	E. & J. Gallo Winery	Detection of fungal pathogens
US6582936B1 (en)	1997-12-12	2003-06-24	The Regents Of The University Of California	Methods for making nucleic acids
US6248519B1 (en)	1998-03-11	2001-06-19	E & J Gallo Winery	Detection of fermentation-related microorganisms
US7045610B2 (en)	1998-04-03	2006-05-16	Epoch Biosciences, Inc.	Modified oligonucleotides for mismatch discrimination
CA2328602A1 (en)	1998-05-06	1999-11-11	University Of Iowa Research Foundation	Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
JP2002514397A (ja)	1998-05-14	2002-05-21	コーリーファーマシューティカルゲーエムベーハー	ＣｐＧオリゴヌクレオチドを用いる造血調節の方法
US6242589B1 (en)	1998-07-14	2001-06-05	Isis Pharmaceuticals, Inc.	Phosphorothioate oligonucleotides having modified internucleoside linkages
US6867294B1 (en)	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
AU764532B2 (en)	1998-07-27	2003-08-21	University Of Iowa Research Foundation, The	Stereoisomers of CpG oligonucleotides and related methods
ES2257068T3 (es)	1998-08-10	2006-07-16	Antigenics Inc.	Mezclas de adyuvantes de cpg y saponinas y metodos de empleo de las mismas.
WO2000023444A1 (en) *	1998-10-21	2000-04-27	Abbott Laboratories	5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US6995259B1 (en)	1998-10-23	2006-02-07	Sirna Therapeutics, Inc.	Method for the chemical synthesis of oligonucleotides
WO2000031110A1 (en)	1998-11-25	2000-06-02	Isis Pharmaceuticals, Inc.	Identification of disease predictive nucleic acids
US6451524B1 (en)	1998-11-25	2002-09-17	Isis Pharmaceuticals, Inc.	Identification of disease predictive nucleic acids
US6379942B1 (en)	1998-12-21	2002-04-30	Genencor International, Inc.	Chemically modified enzymes with multiple charged variants
AU1853600A (en)	1999-01-06	2000-07-24	Choong-Chin Liew	Method for the detection of gene transcripts in blood and uses thereof
US6265172B1 (en)	1999-02-08	2001-07-24	University Of Kentucky	Diagnostic test and therapy for manganese superoxide dismutate (mNsod) associated diseases
US6121437A (en)	1999-03-16	2000-09-19	Isis Pharmaceuticals, Inc.	Phosphate and thiophosphate protecting groups
US6506594B1 (en)	1999-03-19	2003-01-14	Cornell Res Foundation Inc	Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
GB9907245D0 (en)	1999-03-29	1999-05-26	Goldsborough Andrew	Cleavage of nucleic acids from solid supports
JP3072345B1 (ja)	1999-03-31	2000-07-31	農林水産省家畜衛生試験場長	豚丹毒菌の組換えサブユニットワクチン
US5998148A (en)	1999-04-08	1999-12-07	Isis Pharmaceuticals Inc.	Antisense modulation of microtubule-associated protein 4 expression
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
US6300069B1 (en)	1999-05-03	2001-10-09	Qiagen Gmbh	Generation and amplification of nucleic acids from ribonucleic acids
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
US6271004B1 (en)	1999-06-25	2001-08-07	Display Systems Biotech A/S	Method for improved reverse transcription at high temperatures
US6066500A (en)	1999-06-25	2000-05-23	Isis Pharmaceuticals Inc.	Antisense modulation of Beta catenin expression
US6414135B1 (en)	1999-07-07	2002-07-02	Isis Pharmaceuticals, Inc.	C3′-methylene hydrogen phosphonate monomers and related compounds
US20030092647A1 (en)	2001-08-08	2003-05-15	Crooke Rosanne M.	Antisense modulation of cholesteryl ester transfer protein expression
US6147200A (en)	1999-08-19	2000-11-14	Isis Pharmaceuticals, Inc.	2'-O-acetamido modified monomers and oligomers
US7264932B2 (en)	1999-09-24	2007-09-04	Applera Corporation	Nuclease inhibitor cocktail
SK287400B6 (sk)	1999-09-25	2010-08-09	University Of Iowa Research Foundation	Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie
US6949520B1 (en)	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
ATE333284T1 (de)	1999-09-27	2006-08-15	Coley Pharm Group Inc	Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon
US20020082227A1 (en)	1999-09-30	2002-06-27	Scott Henry	Use of oligonucleotides for inhibition of complement activation
WO2001025488A2 (en)	1999-10-06	2001-04-12	Quark Biotech, Inc.	Method for enrichment of natural antisense messenger rna
GB9924285D0 (en)	1999-10-14	1999-12-15	Avecia Ltd	Process
US20010055761A1 (en)	1999-10-29	2001-12-27	Agilent Technologies	Small scale dna synthesis using polymeric solid support with functionalized regions
FR2800750B1 (fr) *	1999-11-05	2003-01-31	Centre Nat Rech Scient	Proteines membranaires ctl (choline transporter like) impliquees dans le transport de la choline
WO2001040515A1 (en)	1999-11-12	2001-06-07	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6322985B1 (en)	1999-12-27	2001-11-27	Technion Research And Development Foundation Ltd.	Abundant, well distributed and hyperpolymorphic simple sequence repeats in prokaryote genomes and use of same for prokaryote classification and typing
AU2743801A (en)	1999-12-30	2001-07-16	Cabot Corporation	Sensors with improved properties
WO2001050349A1 (en)	1999-12-30	2001-07-12	Rutgers, The State University Of New Jersey	Electronic document customization and transformation utilizing user feedback
US6649750B1 (en)	2000-01-05	2003-11-18	Isis Pharmaceuticals, Inc.	Process for the preparation of oligonucleotide compounds
US6159697A (en)	2000-01-19	2000-12-12	Isis Pharmaceuticals, Inc.	Antisense modulation of Smad7 expression
US7585847B2 (en)	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
US6495677B1 (en)	2000-02-15	2002-12-17	Kanda S. Ramasamy	Nucleoside compounds
CA2335389A1 (en)	2000-03-01	2001-09-01	Message Pharmaceuticals, Inc.	Novel bacterial rnase p proteins and their use in identifying antibacterial compounds
GB0004889D0 (en)	2000-03-01	2000-04-19	Avecia Ltd	Synthesis of oligonucleotides
AU2001245823A1 (en)	2000-03-17	2001-10-03	Corixa Corporation	Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
DE10019756A1 (de)	2000-04-20	2001-10-25	Bayer Ag	Verfahren zur Herstellung von superabsorbierenden Polymeren aus Polyacrylnitrilen
TR200402442T4 (tr)	2000-04-20	2004-12-21	F.Hoffmann-La Roche Ag	Pirolidin ve piperidin türevleri ve bunların nörodejeneratif bozuklukların tedavisinde kullanımları
US20020013287A1 (en)	2000-05-09	2002-01-31	Reliable Biopharmaceuticals, Inc. St Louis Missouri	Polymeric compounds useful as prodrugs
US6492171B2 (en)	2000-05-16	2002-12-10	Isis Pharmaceuticals, Inc.	Antisense modulation of TERT expression
US6815542B2 (en)	2000-06-16	2004-11-09	Ribapharm, Inc.	Nucleoside compounds and uses thereof
CA2416631C (en)	2000-08-03	2011-11-22	F. Hoffmann-La Roche Ag	Nucleic acid binding compounds containing pyrazolo[3,4-d]pyrimidine analogues of purin-2,6-diamine and their uses
US6725412B1 (en)	2000-08-15	2004-04-20	Dolby Laboratories Licensing Corporation	Low latency data encoder
US6809195B1 (en)	2000-08-16	2004-10-26	Isis Pharmaceuticals, Inc.	Process for the preparation of oligonucleotides
US6559279B1 (en)	2000-09-08	2003-05-06	Isis Pharmaceuticals, Inc.	Process for preparing peptide derivatized oligomeric compounds
EP1366077B1 (en)	2000-09-15	2011-05-25	Coley Pharmaceutical GmbH	PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
EP1191097A1 (en)	2000-09-21	2002-03-27	Leids Universitair Medisch Centrum	Induction of exon skipping in eukaryotic cells
GB0024752D0 (en)	2000-10-10	2000-11-22	Univ Belfast	Oxidative halogenation of aromatic compounds
BR0114786A (pt)	2000-10-18	2003-08-12	Glaxosmithkline Biolog Sa	Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição
US6372492B1 (en)	2000-10-30	2002-04-16	Isis Pharmaceuticals, Inc.	Antisense modulation of talin expression
US6682889B1 (en)	2000-11-08	2004-01-27	Becton, Dickinson And Company	Amplification and detection of organisms of the Chlamydiaceae family
NL1016978C2 (nl)	2000-12-22	2002-06-25	Robert Jan Colenbrander	Inrichting en werkwijze voor het verpakken en bereiden van voedsel en werkwijze voor het vervaardigen van een dergelijke inrichting.
CZ20032005A3 (en)	2001-01-22	2004-04-14	Merck & Co., Inc.	Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US8008459B2 (en)	2001-01-25	2011-08-30	Evolva Sa	Concatemers of differentially expressed multiple genes
JP2004525624A (ja)	2001-01-25	2004-08-26	エボルババイオテックアクティーゼルスカブ	細胞コレクションのライブラリー
NZ526507A (en)	2001-01-26	2005-07-29	Commw Scient Ind Res Org	Methods and means for producing efficient silencing construct using recombinational cloning
US20050277133A1 (en)	2001-05-18	2005-12-15	Sirna Therapeutics, Inc.	RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
WO2002097134A2 (en)	2001-05-25	2002-12-05	Isis Pharmaceuticals, Inc.	Modified peptide nucleic acid
GB0113523D0 (en) *	2001-06-04	2001-07-25	Torotrak Dev Ltd	An Hydraulic control circuit for a continuosly variable transmission
US20030069410A1 (en)	2001-06-14	2003-04-10	Isis Pharmaceuticals, Inc.	Methods for preparing oligonucleotides having chiral phosphorothioate linkages
US20050019915A1 (en)	2001-06-21	2005-01-27	Bennett C. Frank	Antisense modulation of superoxide dismutase 1, soluble expression
HUP0400346A2 (en)	2001-06-29	2007-08-28	Chiron Corp	Hcv e1e2 vaccine compositions
WO2003004602A2 (en)	2001-07-03	2003-01-16	Isis Pharmaceuticals, Inc.	Nuclease resistant chimeric oligonucleotides
US7205399B1 (en)	2001-07-06	2007-04-17	Sirna Therapeutics, Inc.	Methods and reagents for oligonucleotide synthesis
US6440739B1 (en)	2001-07-17	2002-08-27	Isis Pharmaceuticals, Inc.	Antisense modulation of glioma-associated oncogene-2 expression
US7425545B2 (en)	2001-07-25	2008-09-16	Isis Pharmaceuticals, Inc.	Modulation of C-reactive protein expression
US7407943B2 (en)	2001-08-01	2008-08-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein B expression
US6455308B1 (en)	2001-08-01	2002-09-24	Isis Pharmaceuticals, Inc.	Antisense modulation of serum amyloid A4 expression
US7888324B2 (en)	2001-08-01	2011-02-15	Genzyme Corporation	Antisense modulation of apolipoprotein B expression
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en)	2001-08-07	2007-08-21	Isis Pharmaceuticals, Inc.	Modulation of apolipoprotein (a) expression
WO2003020884A2 (en)	2001-08-14	2003-03-13	The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services	Method for rapid generation of mature dendritic cells
EP1418877A2 (en)	2001-08-24	2004-05-19	Massachusetts Institute Of Technology	Reagents that facilitate the purification of compounds synthesized on a solid support
US7049122B2 (en)	2001-09-21	2006-05-23	Academia Sinica	Mutant-type lipases and applications thereof
US6933288B2 (en)	2002-02-04	2005-08-23	Isis Pharmaceuticals, Inc.	Pyranosyl cytosines: pharmaceutical formulations and methods
JP4348044B2 (ja)	2002-02-12	2009-10-21	株式会社キラルジェン	立体規則性の高いジヌクレオシドホスホロチオエートの製造法
US20040149587A1 (en)	2002-02-15	2004-08-05	George Hradil	Electroplating solution containing organic acid complexing agent
US20030159938A1 (en)	2002-02-15	2003-08-28	George Hradil	Electroplating solution containing organic acid complexing agent
US8232383B2 (en)	2002-02-20	2012-07-31	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050096284A1 (en)	2002-02-20	2005-05-05	Sirna Therapeutics, Inc.	RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
RU2004128943A (ru)	2002-02-28	2005-04-20	Байота, Инк. (Us)	Средства, имитирующие нуклеотиды, и их пролекарственные формы
EP1485396A2 (en)	2002-02-28	2004-12-15	Biota, Inc.	Nucleoside 5'-monophosphate mimics and their prodrugs
US7288376B2 (en)	2002-03-22	2007-10-30	Council Of Scientific And Industrial Research	Method of detection of SP-A2 gene variants useful for prediction of predisposition to aspergillosis
US20040102394A1 (en)	2002-11-23	2004-05-27	Isis Pharmaceuticals Inc.	Modulation of huntingtin interacting protein 2 expression
US7247621B2 (en)	2002-04-30	2007-07-24	Valeant Research & Development	Antiviral phosphonate compounds and methods therefor
AU2003237875A1 (en)	2002-05-15	2003-12-02	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein b expression
AU2003241621A1 (en)	2002-05-24	2003-12-12	Isis Pharmaceuticals, Inc.	Oligonucleotides having modified nucleoside units
WO2003099840A1 (en)	2002-05-24	2003-12-04	Isis Pharmaceuticals, Inc.	Oligonucleotides having modified nucleoside units
US7507808B2 (en)	2002-12-12	2009-03-24	Isis Pharmaceuticals, Inc.	Modulation of endothelial lipase expression
WO2003106477A1 (en)	2002-06-01	2003-12-24	Isis Pharmaceuticals, Inc.	Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
US20040005338A1 (en)	2002-06-20	2004-01-08	Cytos Biotechnology Ag	Packaged virus-like particles for use as adjuvants: method of preparation and use
WO2004003228A1 (en)	2002-07-01	2004-01-08	Unisearch Limited	Genotyping method
AU2003254334A1 (en)	2002-07-10	2004-02-02	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	Rna-interference by single-stranded rna molecules
US20040023905A1 (en)	2002-07-31	2004-02-05	Isis Pharmaceuticals Inc.	Antisense modulation of LAR expression
US20050042646A1 (en)	2002-08-05	2005-02-24	Davidson Beverly L.	RNA interference suppresion of neurodegenerative diseases and methods of use thereof
US20050255086A1 (en)	2002-08-05	2005-11-17	Davidson Beverly L	Nucleic acid silencing of Huntington's Disease gene
US20080274989A1 (en)	2002-08-05	2008-11-06	University Of Iowa Research Foundation	Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
WO2004014933A1 (en)	2002-08-07	2004-02-19	University Of Massachusetts	Compositions for rna interference and methods of use thereof
AU2003259735A1 (en)	2002-08-08	2004-02-25	Sirna Therapeutics, Inc.	Small-mer compositions and methods of use
UA88255C2 (en)	2002-08-19	2009-10-12	Коли Фармасьютикал Групп, Инк.	Immunostimulatory oligonucleotide
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
US7414116B2 (en)	2002-08-23	2008-08-19	Illumina Cambridge Limited	Labelled nucleotides
JP2005538186A (ja)	2002-09-13	2005-12-15	レプリコールインコーポレーティッド	非配列相補性の抗ウイルス性オリゴヌクレオチド
US7030230B2 (en)	2002-10-25	2006-04-18	Isis Pharmaceuticals, Inc.	Process of purifying phosphoramidites
MXPA05004588A (es)	2002-10-29	2005-12-14	Coley Pharmaceutical Group Ltd	Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
DE20216677U1 (de)	2002-10-29	2003-03-13	TRW Automotive Electronics & Components GmbH & Co.KG, 67677 Enkenbach-Alsenborn	Luftausströmer mit Getränkehalter
AU2003290597A1 (en)	2002-11-05	2004-06-03	Isis Pharmaceuticals, Inc.	Modified oligonucleotides for use in rna interference
AU2003295389A1 (en)	2002-11-05	2004-06-03	Isis Pharmaceuticals, Inc.	Conjugated oligomeric compounds and their use in gene modulation
AU2003291753B2 (en)	2002-11-05	2010-07-08	Isis Pharmaceuticals, Inc.	Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
AU2003291721A1 (en)	2002-11-05	2004-06-03	Isis Pharmaceuticals, Inc.	Phosphorous-linked oligomeric compounds and their use in gene modulation
US7381527B2 (en)	2002-11-06	2008-06-03	Council Of Scientific And Industrial Research	Method of detection of SP-A2 gene variants
EP1569695B1 (en)	2002-11-13	2013-05-15	Genzyme Corporation	Antisense modulation of apolipoprotein b expression
US7511131B2 (en)	2002-11-13	2009-03-31	Genzyme Corporation	Antisense modulation of apolipoprotein B expression
EP2284266B1 (en)	2002-11-14	2013-11-06	Thermo Fisher Scientific Biosciences Inc.	siRNA targeting tp53
CA2518475C (en)	2003-03-07	2014-12-23	Alnylam Pharmaceuticals, Inc.	Irna agents comprising asymmetrical modifications
AU2003225705A1 (en)	2003-03-07	2004-09-30	Ribapharm Inc.	Cytidine analogs and methods of use
CA2524255C (en)	2003-03-21	2014-02-11	Academisch Ziekenhuis Leiden	Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
GB0306657D0 (en)	2003-03-24	2003-04-30	Avecia Ltd	Process and compounds
RU2351362C2 (ru)	2003-03-26	2009-04-10	Цитос Байотекнолоджи Аг	КОНЪЮГАТЫ ПЕПТИДА Melan-A, АНАЛОГА ВИРУСОПОДОБНОЙ ЧАСТИЦЫ
US7537767B2 (en)	2003-03-26	2009-05-26	Cytis Biotechnology Ag	Melan-A- carrier conjugates
ITRM20030149A1 (it)	2003-04-02	2004-10-03	Giuliani Spa	Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US7598227B2 (en)	2003-04-16	2009-10-06	Isis Pharmaceuticals Inc.	Modulation of apolipoprotein C-III expression
US20050261237A1 (en)	2003-04-25	2005-11-24	Boojamra Constantine G	Nucleoside phosphonate analogs
US7407965B2 (en)	2003-04-25	2008-08-05	Gilead Sciences, Inc.	Phosphonate analogs for treating metabolic diseases
US7432261B2 (en)	2003-04-25	2008-10-07	Gilead Sciences, Inc.	Anti-inflammatory phosphonate compounds
US7470724B2 (en)	2003-04-25	2008-12-30	Gilead Sciences, Inc.	Phosphonate compounds having immuno-modulatory activity
EP1628685B1 (en)	2003-04-25	2010-12-08	Gilead Sciences, Inc.	Antiviral phosphonate analogs
US7452901B2 (en)	2003-04-25	2008-11-18	Gilead Sciences, Inc.	Anti-cancer phosphonate analogs
CN101410120A (zh)	2003-04-25	2009-04-15	吉里德科学公司	抗炎的膦酸酯化合物
KR20060061930A (ko)	2003-04-25	2006-06-08	길리애드 사이언시즈, 인코포레이티드	항암성 포스포네이트 유사체
WO2004096233A2 (en)	2003-04-25	2004-11-11	Gilead Sciences, Inc.	Nucleoside phosphonate conjugates
US20090247488A1 (en)	2003-04-25	2009-10-01	Carina Cannizzaro	Anti-inflammatory phosphonate compounds
WO2005002626A2 (en)	2003-04-25	2005-01-13	Gilead Sciences, Inc.	Therapeutic phosphonate compounds
US7045306B2 (en)	2003-04-28	2006-05-16	The General Hospital Corporation	Method for identifying compounds in vitro that modulate the dysregulation of transcription of transcription mediated by mutant huntingtin protein
US7214491B2 (en)	2003-05-07	2007-05-08	E. I. Du Pont De Nemours And Company	Δ-12 desaturase gene suitable for altering levels of polyunsaturated fatty acids in oleaginous yeasts
JP4179562B2 (ja)	2003-05-14	2008-11-12	独立行政法人科学技術振興機構	ハンチンチン遺伝子の発現抑制
US7541344B2 (en)	2003-06-03	2009-06-02	Eli Lilly And Company	Modulation of survivin expression
WO2005007672A2 (en)	2003-06-20	2005-01-27	Coley Pharmaceutical Gmbh	Small molecule toll-like receptor (tlr) antagonists
CA2533701A1 (en)	2003-07-31	2005-02-17	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding rnas
JP2011088935A (ja)	2003-08-08	2011-05-06	Chiralgen Ltd	リン原子修飾ヌクレオチド類縁体の製造のための光学活性ヌクレオシド３’−ホスホロアミダイト
JP2005089441A (ja)	2003-08-08	2005-04-07	Toudai Tlo Ltd	立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法
US7825235B2 (en)	2003-08-18	2010-11-02	Isis Pharmaceuticals, Inc.	Modulation of diacylglycerol acyltransferase 2 expression
MXPA06001974A (es)	2003-08-21	2006-05-31	Univ Griffith	Nuevos oxidos de sulfenamida.
EP1664072A1 (en)	2003-08-21	2006-06-07	Griffith University	Novel sulfenamides
ATE486883T1 (de)	2003-08-27	2010-11-15	Biota Scient Management	Neue tricyclische nukleoside oder nukleotide als therapeutische mittel
WO2005021570A1 (ja)	2003-08-28	2005-03-10	Gene Design, Inc.	Ｎ−０結合性架橋構造型新規人工核酸
WO2005023828A1 (ja)	2003-09-02	2005-03-17	Takeshi Wada	リボヌクレオチド又はリボヌクレオチド誘導体の製造方法
WO2005028494A1 (ja)	2003-09-02	2005-03-31	Takeshi Wada	５'-ホスフィチル化モノマーおよびh-ホスホネートオリゴヌクレオチド誘導体の製造方法
US20050053981A1 (en)	2003-09-09	2005-03-10	Swayze Eric E.	Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20050074801A1 (en)	2003-09-09	2005-04-07	Monia Brett P.	Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
CN100393209C (zh)	2003-09-09	2008-06-11	杰龙公司	用于端粒酶抑制的改性寡核苷酸
US8680063B2 (en)	2003-09-12	2014-03-25	University Of Massachusetts	RNA interference for the treatment of gain-of-function disorders
CA2579638C (en)	2003-09-12	2016-04-19	University Of Massachusetts	Rna interference targeting non-disease causing single nucleotide polymorphisms within a gene encoding a gain-of-function mutant huntingtin protein
AU2003304537A1 (en)	2003-10-16	2004-06-06	Form Puller Tool Co., Inc.	Device for removing modular forms
AP2006003611A0 (en)	2003-10-30	2006-06-30	Coley Pharm Gmbh	C-class oligonucleotide analogs with enhanced immunostimulatory potency
US20050239102A1 (en)	2003-10-31	2005-10-27	Verdine Gregory L	Nucleic acid binding oligonucleotides
US7846436B2 (en)	2003-11-28	2010-12-07	Chemgenes Corporation	Oligonucleotides and related compounds
WO2005063983A1 (en)	2003-12-29	2005-07-14	Galapagos Genomics N.V.	Modulators of bone homeostasis identified in a high-throughput screen
JP4945129B2 (ja)	2004-01-27	2012-06-06	株式会社キラルジェン	フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法
US20050176045A1 (en)	2004-02-06	2005-08-11	Dharmacon, Inc.	SNP discriminatory siRNA
EP1725250A2 (en)	2004-02-18	2006-11-29	Frutarom Ltd.	Method for the preparation of peptide-oligonucleotide conjugates
JP3976742B2 (ja)	2004-02-27	2007-09-19	江守商事株式会社	インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
WO2005085272A1 (ja)	2004-03-05	2005-09-15	Takeshi Wada	ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法
JP4865544B2 (ja)	2004-03-25	2012-02-01	株式会社キラルジェン	立体規則性の高いリボヌクレオチド類縁体及びデオキシリボヌクレオチド類縁体の製造法
US20050244869A1 (en)	2004-04-05	2005-11-03	Brown-Driver Vickie L	Modulation of transthyretin expression
US20050267300A1 (en)	2004-04-05	2005-12-01	Muthiah Manoharan	Processes and reagents for oligonucleotide synthesis and purification
TWI350168B (en) *	2004-05-07	2011-10-11	Incyte Corp	Amido compounds and their use as pharmaceuticals
EP1753881A2 (en)	2004-05-27	2007-02-21	The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services	Differential expression of molecules associated with acute stroke
US7759318B1 (en)	2004-05-28	2010-07-20	Isis Pharmaceuticals, Inc.	Identification of novel pathways, genes and promoter motifs regulating adipogenesis
AU2005252662B2 (en)	2004-06-03	2011-08-18	Isis Pharmaceuticals, Inc.	Double strand compositions comprising differentially modified strands for use in gene modulation
EP3228711A1 (en)	2004-06-28	2017-10-11	The University Of Western Australia	Antisense oligonucleotides for inducing exon skipping and methods of use thereof
DK2997980T3 (da)	2004-08-10	2018-03-26	Kastle Therapeutics Llc	Fremgangsmåder til modulation af liproprotein- og cholesterolniveauer hos mennesker
CA2577922C (en)	2004-08-26	2013-06-25	Nippon Shinyaku Co., Ltd.	Phosphoramidite compound and method for producing oligo-rna
US20070066551A1 (en)	2004-09-07	2007-03-22	Keefe Anthony D	Aptamer medicinal chemistry
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
US20090203132A1 (en)	2004-09-09	2009-08-13	Swayze Eric E	Pyrrolidinyl groups for attaching conjugates to oligomeric compounds
WO2006034348A2 (en)	2004-09-17	2006-03-30	Isis Pharmaceuticals, Inc.	Enhanced antisense oligonucleotides
AU2005295756B2 (en)	2004-10-13	2012-02-02	Isis Parmaceuticals, Inc.	Antisense modulation of PTP1B expression
US9120774B2 (en)	2004-11-03	2015-09-01	University Of Kansas	Novobiocin analogues having modified sugar moieties
US7622451B2 (en)	2004-11-03	2009-11-24	University Of Kansas	Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
WO2006050501A2 (en)	2004-11-03	2006-05-11	University Of Kansas	Novobiocin analogues as anticancer agents
US8212012B2 (en)	2004-11-03	2012-07-03	University Of Kansas	Novobiocin analogues having modified sugar moieties
US8212011B2 (en)	2004-11-03	2012-07-03	University Of Kansas	Novobiocin analogues
KR100721928B1 (ko)	2004-11-05	2007-05-28	주식회사 바이오씨에스	ＣｐＧ 올리고데옥시뉴클레오티드를 함유하는 피부질환의치료 또는 예방용 약학적 조성물
EP1657307A1 (en)	2004-11-16	2006-05-17	Immunotech S.A.	Oligonucleotides that induce the secretion of GM-CSF
EP1819365B1 (en)	2004-12-09	2014-07-02	Alnylam Pharmaceuticals Inc.	Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
WO2006065751A2 (en)	2004-12-13	2006-06-22	Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
WO2006066260A2 (en)	2004-12-17	2006-06-22	Thiosense, Inc.	Compositions of and methods for producing phosphorus-chiral monomers and oligomers
US20070099851A1 (en)	2004-12-30	2007-05-03	Linn Gregory S	Stable analogues of ribose-1-phosphate and methods for treating diabetes and other metabolic disorders
US20060183763A1 (en) *	2004-12-31	2006-08-17	Pfizer Inc	Novel pyrrolidyl derivatives of heteroaromatic compounds
JP4836145B2 (ja)	2005-01-28	2011-12-14	クウォン，ヒュン−ジョ	マイコバクテリアに由来する、免疫機能刺激用、免疫疾患治療用、アトピー性皮膚炎治療用および／または正常免疫細胞保護用オリゴヌクレオチド
JP2008531018A (ja)	2005-02-24	2008-08-14	コーリーファーマシューティカルグループ，インコーポレイテッド	免疫刺激性オリゴヌクレオチド
WO2006137953A1 (en)	2005-04-01	2006-12-28	The Regents Of The Univerisity Of California	Phosphono-pent-2-en-1-yl nucleosides and analogs
SI1877070T1 (sl)	2005-05-05	2009-06-30	Antisense Pharma Gmb H	Terapevtska uporaba TGF-beta2 protismiselnih oligonukleotidov
US7902352B2 (en)	2005-05-06	2011-03-08	Medtronic, Inc.	Isolated nucleic acid duplex for reducing huntington gene expression
EP1885854B1 (en)	2005-05-06	2012-10-17	Medtronic, Inc.	Methods and sequences to suppress primate huntington gene expression
EP2644700A1 (en)	2005-06-23	2013-10-02	Isis Pharmaceuticals, Inc.	Compositions and methods for modulation of SMN2 splicing
US9133517B2 (en)	2005-06-28	2015-09-15	Medtronics, Inc.	Methods and sequences to preferentially suppress expression of mutated huntingtin
ATE522626T1 (de)	2005-06-28	2011-09-15	Medtronic Inc	Verfahren und nukleotid-sequenzen, die bevorzugt die expression eines mutierten huntingtin-genes unterdrücken
EP1948600B1 (en)	2005-07-05	2014-04-16	The President & Fellows Of Harvard College	Liver targeted conjugates
JP4984634B2 (ja)	2005-07-21	2012-07-25	ソニー株式会社	物理情報取得方法および物理情報取得装置
BRPI0615958B8 (pt)	2005-07-28	2021-05-25	Id Fish Tech Inc	composição para aumentar a permeabilidade de paredes celulares e membranas celulares de mycobacterium sp. e método para detectar um alvo em uma célula
CA2620856C (en)	2005-08-29	2017-11-28	Isis Pharmaceuticals, Inc.	Methods for use in modulating mir-122a
EP1937312B1 (en)	2005-08-30	2016-06-29	Ionis Pharmaceuticals, Inc.	Chimeric oligomeric compounds for modulation of splicing
US7700567B2 (en)	2005-09-29	2010-04-20	Supergen, Inc.	Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070077993A1 (en)	2005-09-30	2007-04-05	Midgley Timothy M	Method and apparatus for collecting user game play data and crediting users in a gaming environment
KR101455081B1 (ko)	2005-10-12	2014-10-27	이데라 파마슈티칼즈, 인코포레이티드	톨―유사 수용체 기초 면역 반응을 조절하기 위한 면역조절 올리고누클레오티드 (ｉｒｏ)
US9308252B2 (en)	2005-10-27	2016-04-12	Cook Biotech, Inc.	Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
AU2006305886C1 (en)	2005-10-28	2011-03-17	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of huntingtin gene
CN101466834B (zh)	2005-10-28	2013-09-25	东曹株式会社	制备类胡萝卜素合成性微生物的方法和生产类胡萝卜素的方法
RU2008118144A (ru)	2005-11-11	2009-11-20	Пфайзер Инк. (US)	Комбинации иммуномодулирующих олигоодезоксинуклеотидов и способы их применения
WO2007064291A1 (en)	2005-11-30	2007-06-07	Jyoti Chattopadhyaya	Method and compounds for rna synthesis
CA2632968A1 (en)	2005-12-02	2007-06-07	Isis Pharmaceuticals, Inc.	Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
US8076303B2 (en)	2005-12-13	2011-12-13	Spring Bank Pharmaceuticals, Inc.	Nucleotide and oligonucleotide prodrugs
PL1979356T3 (pl) *	2005-12-21	2014-01-31	Pfizer Prod Inc	Karbonyloaminopirolopirazole, inhibitory kinazy białkowej
EP3210633B1 (en)	2006-01-26	2019-06-19	Ionis Pharmaceuticals, Inc.	Compositions and their uses directed to huntingtin
DK1984381T3 (da)	2006-01-27	2010-11-01	Isis Pharmaceuticals Inc	6-modificerede bicycliske nukleinsyreanaloger
ES2526879T3 (es)	2006-02-15	2015-01-16	Adiutide Pharmaceuticals Gmbh	Composiciones y procedimientos para formulaciones de oligonucleótidos
US7759470B2 (en)	2006-02-20	2010-07-20	Roche Diagnostics Operations, Inc.	Labeling reagent
IN2014CN00532A (da) *	2006-03-06	2015-04-03	Japan Tobacco Inc
US8383660B2 (en) *	2006-03-10	2013-02-26	Pfizer Inc.	Dibenzyl amine compounds and derivatives
EP2001871B1 (en)	2006-03-31	2014-07-16	Applied Biosystems, LLC	Rhodamine-labeled oligonucleotides
US8088582B2 (en)	2006-04-06	2012-01-03	Ibis Biosciences, Inc.	Compositions for the use in identification of fungi
ES2348122T3 (es) *	2006-04-20	2010-11-30	F. Hoffmann-La Roche Ag	Derivados de diazepano moduladores de receptores de quimioquina.
ES2396453T3 (es)	2006-04-24	2013-02-21	Sigma Alimentos, S.A. De C.V.	Método para la detección y cuantificación múltiple y simultánea de patógenos mediante la reacción en cadena de la polimerasa en tiempo real
US20130129752A1 (en)	2006-04-25	2013-05-23	Immune Disease Institute, Inc.	Targeted delivery to leukocytes using protein carriers
GB0608838D0 (en)	2006-05-04	2006-06-14	Novartis Ag	Organic compounds
US8158598B2 (en)	2006-05-05	2012-04-17	Isis Pharmaceuticals, Inc.	Compositions and their uses directed to PTPR alpha
BRPI0711429A2 (pt)	2006-05-05	2012-10-16	Isis Pharmaceuticals Inc	compostos e métodos para modulas expressão de gccr
US20090012120A1 (en)	2006-05-10	2009-01-08	Board Of Trustees Of Michigan State University	Synthesis of N-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines
US7666854B2 (en)	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
CA2651453C (en)	2006-05-11	2014-10-14	Isis Pharmaceuticals, Inc.	5'-modified bicyclic nucleic acid analogs
EP2034015B1 (en)	2006-05-31	2012-07-11	Toray Industries, Inc.	Immunostimulatory oligonucleotide and pharmaceutical application thereof
US8097596B2 (en)	2006-06-30	2012-01-17	Lakewood-Amedex, Inc.	Compositions and methods for the treatment of muscle wasting
EP2046993A4 (en)	2006-07-07	2010-11-17	Univ Massachusetts	RNA SILENCING COMPOSITIONS, AND METHODS OF TREATING HUNTINGTON CHOREA
US20090093425A1 (en)	2006-07-12	2009-04-09	The Regents Of The University Of California	Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
AU2007275301A1 (en) *	2006-07-20	2008-01-24	Amgen Inc.	Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
GB0614947D0 (en)	2006-07-27	2006-09-06	Isis Innovation	Epitope reduction therapy
AU2007281082A1 (en)	2006-08-04	2008-02-07	Isis Pharmaceuticals, Inc.	Compositions and methods for the modulation of JNK proteins
AT504194B1 (de)	2006-09-07	2008-07-15	Oesterr Rotes Kreuz	Bakteriennachweis
US8138330B2 (en)	2006-09-11	2012-03-20	Sigma-Aldrich Co. Llc	Process for the synthesis of oligonucleotides
NZ575437A (en)	2006-09-27	2012-02-24	Coley Pharm Gmbh	Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
CA2667090C (en)	2006-10-18	2017-02-28	The Nanosteel Company, Inc.	Protective coating for concrete delivery system components
BRPI0717348A2 (pt) *	2006-10-23	2013-10-15	Irm Llc	Composições e processos para inibir captecina proteases
BRPI0718182A2 (pt)	2006-10-26	2014-02-25	Coley Pharm Gmbh	Oligorribonucleotídeos e seus usos.
FR2908414B1 (fr)	2006-11-13	2012-01-20	Centre Nat Rech Scient	Immobilisation de proteines membranaires sur un support par l'intermediaire d'une molecule amphiphile
WO2008060621A2 (en) *	2006-11-17	2008-05-22	Abbott Laboratories	Aminopyrrolidines as chemokine receptor antagonists
TW200838551A (en)	2006-11-27	2008-10-01	Isis Pharmaceuticals Inc	Methods for treating hypercholesterolemia
US8093222B2 (en)	2006-11-27	2012-01-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
CA2671883A1 (en)	2006-12-12	2008-06-19	Idera Pharmaceuticals, Inc.	Synthetic agonists of tlr9
UY30892A1 (es)	2007-02-07	2008-09-02	Smithkline Beckman Corp	Inhibidores de la actividad akt
EP2125852B1 (en)	2007-02-15	2016-04-06	Ionis Pharmaceuticals, Inc.	5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
AU2008230886B9 (en)	2007-03-24	2014-09-04	Kastle Therapeutics, Llc	Administering antisense oligonucleotides complementary to human apolipoprotein B
US7960353B2 (en)	2007-05-10	2011-06-14	University Of Kansas	Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
PT2158316E (pt)	2007-05-11	2015-07-20	Adynxx Inc	Expressão génica e dor
US8222407B2 (en)	2007-05-24	2012-07-17	Kyorin Pharmaceutical Co., Ltd.	Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position
GB0710186D0 (en)	2007-05-29	2007-07-04	Texas Instr Denmark	PWM loop with minimum allasing error property
US8278425B2 (en)	2007-05-30	2012-10-02	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
NZ581364A (en) *	2007-06-05	2011-10-28	Nsab Af Neurosearch Sweden Ab	Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
US8278426B2 (en)	2007-06-08	2012-10-02	Isis Pharmaceuticals, Inc.	Carbocyclic bicyclic nucleic acid analogs
EP2164865A2 (en)	2007-06-13	2010-03-24	Hochschule Mannheim	Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds
ATE462787T1 (de)	2007-06-18	2010-04-15	Commissariat Energie Atomique	Reversibles sirna-silencing eines mutierten und endogenen huntington-wildtypgens und dessen anwendung zur behandlung von morbus huntington
GB0712494D0 (en)	2007-06-27	2007-08-08	Isis Innovation	Substrate reduction therapy
CA2692579C (en)	2007-07-05	2016-05-03	Isis Pharmaceuticals, Inc.	6-disubstituted bicyclic nucleic acid analogs
CA2692161C (en)	2007-07-09	2015-09-29	Idera Pharmaceuticals, Inc.	Stabilized immune modulatory rna (simra) compounds
TWI413530B (zh)	2007-07-20	2013-11-01	Kao Corp	有機聚矽氧
AU2008281281A1 (en)	2007-07-31	2009-02-05	University Of Saskatchewan	Genetic variation in Pro-Melanin-Concentrating Hormone gene affects carcass traits in cattle
EP2185700A4 (en)	2007-08-02	2010-11-24	Texas A & M Univ Sys	Antisense microrna and uses therefor
US8853375B2 (en)	2007-08-15	2014-10-07	Idera Pharmaceuticals, Inc.	Toll like receptor modulators
BRPI0817527A2 (pt)	2007-10-01	2017-05-02	Isis Pharmaceuticals Inc	modulação antissenso da expressão do receptor de fator de crescimento de fibroblasto humano 4
KR100886139B1 (ko)	2007-11-13	2009-02-27	주식회사 삼천리제약	올리고뉴클레오타이드의 제조방법
AR069869A1 (es)	2007-12-21	2010-02-24	Exelixis Inc	Derivados de benzofuro[3,2-d]pirimidinas inhibidores de proteinquinasas,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer.
TWI340765B (en)	2007-12-26	2011-04-21	Ind Tech Res Inst	Oligonucleotide sequences and dna chip for identifying filamentous microorganisms and the identification method thereof
WO2009089659A1 (en)	2008-01-18	2009-07-23	Shanghai Targetdrug Co., Ltd.	Pyrollidine-based compounds
EP2240768A1 (en)	2008-02-04	2010-10-20	Galapagos N.V.	Target sequences and methods to identify the same, useful in treatment of neurodegenerative diseases
JP2009190983A (ja)	2008-02-12	2009-08-27	Tokyo Institute Of Technology	オリゴヌクレオチド誘導体
US8426378B2 (en)	2008-03-21	2013-04-23	Isis Pharmaceuticals, Inc.	Oligomeric compounds comprising tricyclic nucelosides and methods for their use
WO2009142822A2 (en)	2008-03-26	2009-11-26	Alnylam Pharmaceuticals, Inc.	2-f modified rna interference agents
KR101806314B1 (ko)	2008-04-03	2017-12-07	스프링 뱅크 파마슈티칼스, 인크.	바이러스 감염증을 치료하기 위한 조성물 및 방법
US8350022B2 (en)	2008-04-04	2013-01-08	Universitaet Hamburg	Method for the stereoselective synthesis of phosphorus compounds
US9290534B2 (en)	2008-04-04	2016-03-22	Ionis Pharmaceuticals, Inc.	Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside
US8679750B2 (en)	2008-05-09	2014-03-25	The University Of British Columbia	Methods and compositions for the treatment of Huntington'S disease
CA2726866A1 (en)	2008-05-09	2009-11-12	The University Of British Columbia	Methods and compositions for the treatment of huntington's disease
CA2724418A1 (en)	2008-05-15	2009-11-19	Dynavax Technologies Corporation	Long term disease modification using immunostimulatory oligonucleotides
WO2009143391A2 (en)	2008-05-22	2009-11-26	Isis Pharmaceuticals, Inc	Methods for modulation expression of creb
WO2009143390A2 (en)	2008-05-22	2009-11-26	Isis Pharmaceuticals, Inc.	Methods for modulating expression of rbp4
US8541387B2 (en)	2008-05-22	2013-09-24	Isis Pharmaceuticals, Inc.	Modulation of SMRT expression
WO2009148605A2 (en)	2008-06-04	2009-12-10	Isis Pharmaceuticals, Inc.	Methods for treating hypercholesterolemia
US20110201599A1 (en)	2008-07-03	2011-08-18	Exelixis, Inc.	CDK Modulators
WO2010030849A1 (en)	2008-09-12	2010-03-18	University Of Louisville Research Foundation, Inc.	Compositions and methods for treating cancer,inhibiting proliferation, and inducing cell death
WO2010030858A1 (en)	2008-09-15	2010-03-18	Enanta Pharmaceuticals, Inc.	4'-allene-substituted nucleoside derivatives
EP2346883B1 (en)	2008-09-23	2016-03-23	Scott G. Petersen	Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
EP2356129B1 (en)	2008-09-24	2013-04-03	Isis Pharmaceuticals, Inc.	Substituted alpha-l-bicyclic nucleosides
WO2010036696A1 (en)	2008-09-24	2010-04-01	Isis Pharmaceuticals, Inc.	Cyclohexenyl nucleic acid analogs
EP2344204A4 (en)	2008-10-07	2012-07-04	Harvard College	TELOMERASE INHIBITOR AND METHOD OF USE THEREOF
CA2738957A1 (en)	2008-10-22	2010-04-29	Quark Pharmaceuticals, Inc.	Methods for treating eye disorders
EP2447274B1 (en)	2008-10-24	2017-10-04	Ionis Pharmaceuticals, Inc.	Oligomeric compounds and methods
WO2010048549A2 (en)	2008-10-24	2010-04-29	Isis Pharmaceuticals, Inc.	5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
SG171914A1 (en)	2008-12-02	2011-07-28	Chiralgen Ltd	Method for the synthesis of phosphorus atom modified nucleic acids
CN102307889A (zh)	2008-12-23	2012-01-04	集润德斯股份公司	硫化剂及其用于寡核苷酸合成的用途
WO2010080953A1 (en)	2009-01-08	2010-07-15	Isis Pharmaceuticals, Inc.	Transgenic murine model of human lipoprotein metabolism, hypercholesterolemia and cardiovascular disease
KR20100087540A (ko)	2009-01-28	2010-08-05	삼성전자주식회사	잉크젯 기록용 잉크 조성물
WO2010091301A1 (en)	2009-02-06	2010-08-12	Isis Pharmaceuticals, Inc.	Oligomeric compounds and excipients
MX2011008383A (es)	2009-02-10	2011-09-06	Idera Pharmaceuticals Inc	Agonistas basados en acido ribonucleico sintetico de receptor 7 tipo toll.
EP2438078B1 (en)	2009-02-20	2017-10-25	University Of Kansas	Novobiocin analogues having modified sugar moieties
AU2010221419B2 (en) *	2009-03-02	2015-10-01	Alnylam Pharmaceuticals, Inc.	Nucleic acid chemical modifications
US9107933B2 (en)	2009-03-16	2015-08-18	Isis Pharmaceuticals, Inc.	Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III
US20120007772A1 (en)	2009-03-16	2012-01-12	Paerssinen Aarno Tapio	Controller for a Directional Antenna and Associated Apparatus and Methods
EP2415777B1 (en)	2009-03-31	2015-07-29	Takeda Pharmaceutical Company Limited	Process for producing nucleoside
US8987222B2 (en)	2009-04-08	2015-03-24	University Of Massachusetts	Single nucleotide polymorphism (SNP) targeting therapies for the treatment of huntington'S disease
US20120156138A1 (en)	2009-04-14	2012-06-21	Smith Larry J	Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming
US9260493B2 (en)	2009-05-07	2016-02-16	The Regents Of The University Of California	Transducible delivery of nucleic acids using modified dsRNA binding domains
AU2010256836A1 (en)	2009-06-01	2012-01-19	The Regents Of The University Of California	Nucleic acid delivery compositions and methods of use thereof
TWI549688B (zh)	2009-06-05	2016-09-21	美國疾病傳染研究機構	合成的葡萄吡喃糖基脂質佐劑
NZ624712A (en)	2009-06-17	2015-10-30	Isis Pharmaceuticals Inc	Compositions and methods for modulation of smn2 splicing in a subject
JP5670097B2 (ja)	2009-06-19	2015-02-18	花王株式会社	二層分離型毛髪化粧料
JPWO2010150789A1 (ja)	2009-06-23	2012-12-10	武田薬品工業株式会社	核酸の合成法
WO2011005761A1 (en)	2009-07-06	2011-01-13	Ontorii, Inc	Novel nucleic acid prodrugs and methods use thereof
US8329024B2 (en)	2009-07-06	2012-12-11	Ada Technologies, Inc.	Electrochemical device and method for long-term measurement of hypohalites
US8927513B2 (en)	2009-07-07	2015-01-06	Alnylam Pharmaceuticals, Inc.	5′ phosphate mimics
US20110009477A1 (en)	2009-07-08	2011-01-13	Idera Pharmaceuticals, Inc.	Oligonucleotide-based compounds as inhibitors of toll-like receptors
WO2011010706A1 (ja)	2009-07-23	2011-01-27	武田薬品工業株式会社	Fgf21シスエレメント結合物質
WO2011015573A1 (en)	2009-08-03	2011-02-10	Galapagos Nv	Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015572A1 (en)	2009-08-03	2011-02-10	Galapagos Nv	Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
UA107360C2 (en)	2009-08-05	2014-12-25	Biogen Idec Inc	Bicyclic aryl sphingosine 1-phosphate analogs
WO2011017521A2 (en)	2009-08-06	2011-02-10	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexose nucleic acid analogs
US8927553B2 (en)	2009-08-10	2015-01-06	Daljit Singh Dhanoa	Deuterium-enriched alkyl sulfonamides and uses thereof
KR20170102069A (ko)	2009-09-11	2017-09-06	아이오니스 파마수티컬즈, 인코포레이티드	헌팅틴 발현의 조절
WO2011034072A1 (ja)	2009-09-16	2011-03-24	株式会社キラルジェン	Rna及びその誘導体合成のための新規保護基
WO2011038288A1 (en)	2009-09-25	2011-03-31	Isis Pharmaceuticals, Inc.	Modulation of ttc39 expression to increase hdl
EP2488524B1 (en)	2009-10-15	2013-07-03	Pfizer Inc.	Pyrrolo[2,3-d]pyrimidine compounds
TWI475051B (zh)	2009-11-18	2015-03-01	Kao Corp	Organic polysiloxane
JP5809408B2 (ja)	2009-11-25	2015-11-10	花王株式会社	毛髪化粧料
EP2512246B1 (en) *	2009-12-17	2015-09-30	Merck Sharp & Dohme Corp.	Aminopyrimidines as syk inhibitors
CN102812361A (zh)	2009-12-28	2012-12-05	阿茨拉实验室有限公司	诊断凝胶组合物、制造诊断凝胶组合物的方法
CN102753186B (zh)	2010-01-08	2016-09-14	Isis制药公司	血管生成素样3表达的调节
US8750507B2 (en)	2010-01-25	2014-06-10	Cisco Technology, Inc.	Dynamic group creation for managed key servers
WO2011097643A1 (en)	2010-02-08	2011-08-11	Isis Pharmaceuticals, Inc.	Selective reduction of allelic variants
JP6018506B2 (ja)	2010-02-08	2016-11-02	アイオーニスファーマシューティカルズ，インコーポレーテッドＩｏｎｉｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	対立遺伝子多様体の選択的低減
RS53745B1 (en)	2010-02-10	2015-06-30	Glaxosmithkline Llc	6-AMINO-2 - {[(1S) -1-METYLBUTIL] OKSI} -9- [5- (1-PIPERIDINIL) PENTIL] -7,9-DIHIDRO-8H-PURIN-8-ON-MALEAT
JP5847700B2 (ja)	2010-03-05	2016-01-27	株式会社ＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＪａｐａｎ	リボヌクレオシドホスホロチオエートの製造方法
WO2011127175A1 (en)	2010-04-06	2011-10-13	Isis Pharmaceuticals, Inc.	Modulation of cd130 (gp130) expression
WO2011127307A1 (en)	2010-04-07	2011-10-13	Isis Pharmaceuticals, Inc.	Modulation of cetp expression
WO2011133871A2 (en)	2010-04-22	2011-10-27	Alnylam Pharmaceuticals, Inc.	5'-end derivatives
CN103154014B (zh)	2010-04-28	2015-03-25	Isis制药公司	修饰核苷、其类似物以及由它们制备的寡聚化合物
EP3091027B1 (en)	2010-04-28	2018-01-17	Ionis Pharmaceuticals, Inc.	5' modified nucleosides and oligomeric compounds prepared therefrom
US20130156845A1 (en)	2010-04-29	2013-06-20	Alnylam Pharmaceuticals, Inc.	Lipid formulated single stranded rna
EP2563921B1 (en)	2010-04-30	2016-11-23	Cellectis	Method for modulating double-strand break-induced homologous recombination
GB201008902D0 (en)	2010-05-27	2010-07-14	Imp Innovations Ltd	Membrane enhanced polymer sythesis
US20130253168A1 (en)	2010-08-31	2013-09-26	Steven L. Colletti	Novel single chemical entities and methods for delivery of oligonucleotides
EP2620428B1 (en)	2010-09-24	2019-05-22	Wave Life Sciences Ltd.	Asymmetric auxiliary group
US9238812B2 (en)	2010-09-30	2016-01-19	Lsip, Llc	Agent for suppressing expression of dominant mutant gene
KR101381048B1 (ko)	2010-10-20	2014-04-14	씨제이제일제당 (주)	Ｏ-포스포세린 생산 균주 및 이로부터 생산된 ｏ-포스포세린으로부터 ｌ-시스테인 또는 이의 유도체의 생산방법
EP3327125B1 (en)	2010-10-29	2020-08-05	Sirna Therapeutics, Inc.	Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
EP2638163B1 (en)	2010-11-12	2017-05-17	The General Hospital Corporation	Polycomb-associated non-coding rnas
WO2012073857A1 (ja)	2010-11-30	2012-06-07	株式会社キラルジェン	２'－ｏ－修飾ｒｎａ
US20140050778A1 (en)	2010-12-28	2014-02-20	University Of Rochester	Nucleic acid binding compounds, methods of making, and use thereof
EP3467109A1 (en)	2011-02-08	2019-04-10	Ionis Pharmaceuticals, Inc.	Oligomeric compounds comprising bicyclic nucleotides and uses thereof
WO2012109667A1 (en)	2011-02-12	2012-08-16	University Of Iowa Research Foundation	Therapeutic compounds
US9353371B2 (en)	2011-05-02	2016-05-31	Ionis Pharmaceuticals, Inc.	Antisense compounds targeting genes associated with usher syndrome
FR2975600B1 (fr)	2011-05-24	2013-07-05	Assist Publ Hopitaux De Paris	Agents pour le traitement de tumeurs
DK2734208T3 (da)	2011-07-19	2017-06-19	Wave Life Sciences Ltd	Fremgangsmåder til syntese af funktionaliserede nukleinsyrer
RU2014106024A (ru)	2011-07-19	2015-08-27	Юниверсити Оф Айдахо	Варианты осуществления зонда и способы направленного действия на нуклеиновые кислоты
US20140303235A1 (en)	2011-08-11	2014-10-09	Isis Pharmaceuticals, Inc.	Linkage modified gapped oligomeric compounds and uses thereof
WO2013033223A1 (en)	2011-08-29	2013-03-07	Isis Pharmaceuticals, Inc.	Methods and compounds useful in conditions related to repeat expansion
US20140080896A1 (en)	2011-08-30	2014-03-20	The Regents Of The University Of California	Identification of small molecules that facilitate therapeutic exon skipping
US9896729B2 (en)	2011-08-31	2018-02-20	The University Of Manchester	Method for diagnosing a neurodegenerative disease
WO2013036833A1 (en)	2011-09-09	2013-03-14	Mayo Foundation For Medical Education And Research	Detecting frontotemporal dementia and amyotrophic lateral sclerosis
ES2832531T3 (es)	2011-11-30	2021-06-10	Sarepta Therapeutics Inc	Oligonucleótidos para el tratamiento de enfermedades por expansión de repeticiones
EP2790736B1 (en)	2011-12-12	2018-01-31	Oncoimmunin, Inc.	In vivo delivery of oligonucleotides
CN112386605A (zh)	2011-12-16	2021-02-23	国立大学法人东京医科齿科大学	嵌合的双链核酸
CN102675386B (zh)	2011-12-24	2014-07-02	河南科技大学	一种龙胆苦苷分离提纯方法
US8957042B2 (en)	2012-03-07	2015-02-17	The Texas A&M University System	Cancer treatment targeting non-coding RNA overexpression
EA028928B9 (ru)	2012-03-13	2018-05-31	Джилид Сайэнс, Инк.	2'-замещенные карбануклеозидные аналоги для противовирусного лечения
KR20130114435A (ko)	2012-04-09	2013-10-17	삼성전자주식회사	다수의 전극을 갖는 생분자 검출 장치
PL3604536T3 (pl)	2012-04-23	2024-12-16	Vico Therapeutics B.V.	Modulujące rna oligonukleotydy o ulepszonych właściwościach do leczenia zaburzeń nerwowo-mięśniowych
BR112014029115A8 (pt)	2012-05-22	2018-04-03	Idenix Pharmaceuticals Inc	Composto, composição farmacêutica, e, uso de um composto ou composição
WO2013179412A1 (ja)	2012-05-30	2013-12-05	北海道システム・サイエンス株式会社	高分散性液相支持体を用いたオリゴヌクレオチド合成法
CN107011400B (zh)	2012-07-13	2021-05-25	波涛生命科学有限公司	不对称辅助基团
KR101835401B1 (ko)	2012-07-13	2018-03-08	신 니뽄 바이오메디칼 라보라토리즈, 엘티디.	키랄 핵산 어쥬번트
EP2872147B1 (en)	2012-07-13	2022-12-21	Wave Life Sciences Ltd.	Method for making chiral oligonucleotides
DK2879718T3 (da)	2012-08-06	2023-06-19	Alnylam Pharmaceuticals Inc	Proces til fremstilling af kulhydratkonjugerede RNA-stoffer
EP2885312A4 (en)	2012-08-15	2016-01-20	Isis Pharmaceuticals Inc	PROCESS FOR PREPARING OLIGOMERIC COMPOUNDS USING MODIFIED CAPTURE PROTOCOLS
EP3459549B1 (en)	2012-10-12	2022-04-06	Ionis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
PT2906696T (pt)	2012-10-15	2019-12-16	Univ California	Métodos para modular a expressão de c9orf72
WO2014062736A1 (en)	2012-10-15	2014-04-24	Isis Pharmaceuticals, Inc.	Methods for monitoring c9orf72 expression
AU2013331434B2 (en)	2012-10-15	2019-08-08	Ionis Pharmaceuticals, Inc.	Compositions for modulating C90RF72 expression
EP2725029A1 (en)	2012-10-29	2014-04-30	Laboratoire Biodim	New antibacterial compounds and biological applications thereof
CN104884462A (zh)	2012-10-29	2015-09-02	共晶制药股份有限公司	用于治疗病毒感染和癌症的嘧啶核苷及其单磷酸酯前药
JP6358955B2 (ja)	2012-10-31	2018-07-18	武田薬品工業株式会社	新規修飾核酸
JP2016503300A (ja)	2012-11-15	2016-02-04	ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅＩｎｎｏｖａｔｉｏｎＣｅｎｔｅｒＣｏｐｅｎｈａｇｅｎＡ／Ｓ	抗ＡｐｏＢアンチセンス複合体化合物
JP6463687B2 (ja)	2012-11-26	2019-02-06	ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅＩｎｎｏｖａｔｉｏｎＣｅｎｔｅｒＣｏｐｅｎｈａｇｅｎＡ／Ｓ	Ｆｇｆｒ３の発現の調節のための組成物及び方法
WO2014099941A1 (en)	2012-12-19	2014-06-26	Idenix Pharmaceuticals, Inc.	4'-fluoro nucleosides for the treatment of hcv
MY177989A (en)	2013-01-30	2020-09-28	Hoffmann La Roche	Lna oligonucleotide carbohydrate conjugates
WO2014118272A1 (en)	2013-01-30	2014-08-07	Santaris Pharma A/S	Antimir-122 oligonucleotide carbohydrate conjugates
US10260069B2 (en)	2013-02-04	2019-04-16	Ionis Pharmaceuticals, Inc.	Selective antisense compounds and uses thereof
WO2014130607A1 (en)	2013-02-22	2014-08-28	Sirna Therapeutics, Inc.	SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE
CA2901983A1 (en)	2013-03-01	2014-09-04	National University Corporation Tokyo Medical And Dental University	Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
EP2978317A1 (en)	2013-03-28	2016-02-03	Syngenta Participations AG	Methods of controlling neonicotinoid resistant pests
EA201500984A1 (ru)	2013-03-28	2016-04-29	Зингента Партисипейшнс Аг	Способы контроля устойчивых к неоникотиноидам вредителей
IL296543B2 (en)	2013-05-01	2025-02-01	Ionis Pharmaceuticals Inc	Compositions and methods for modulating HBV and TTR expression
WO2014188001A1 (en)	2013-05-24	2014-11-27	Santaris Pharma A/S	Oligonucleotide modulators of b-cell cll/lymphoma 11a (bcl11a) and uses thereof
DK3015467T3 (da)	2013-05-24	2025-02-10	Ajinomoto Kk	Morpholino-oligonukleotidfremstillingsfremgangsmåde
JP6472087B2 (ja)	2013-05-30	2019-02-27	国立大学法人東京医科歯科大学	治療用オリゴヌクレオチドを送達するための二本鎖剤
CN105324119A (zh)	2013-06-16	2016-02-10	国立大学法人东京医科齿科大学	具有外显子跳跃效应的双链反义核酸
EP3730619A1 (en)	2013-06-21	2020-10-28	Ionis Pharmaceuticals, Inc.	Compositions and methods for modulation of target nucleic acids
EA201592215A1 (ru)	2013-06-27	2016-05-31	Рош Инновейшен Сентер Копенгаген А/С	Антисмысловые олигомеры и их конъюгаты, направленные на пропротеин конвертазу субтилизин/кексин типа 9 (pcsk9)
TW202246503A (zh)	2013-07-19	2022-12-01	美商百健Ｍａ公司	用於調節τ蛋白表現之組合物
US10894963B2 (en)	2013-07-25	2021-01-19	Exicure, Inc.	Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10435430B2 (en)	2013-07-31	2019-10-08	Ionis Pharmaceuticals, Inc.	Methods and compounds useful in conditions related to repeat expansion
CN105579442A (zh)	2013-09-06	2016-05-11	先正达参股股份有限公司	杀虫化合物
EP3052511A4 (en)	2013-10-02	2017-05-31	Moderna Therapeutics, Inc.	Polynucleotide molecules and uses thereof
CN105980401A (zh)	2013-10-03	2016-09-28	现代治疗公司	编码低密度脂蛋白受体的多核苷酸
EP3052627B1 (en)	2013-10-04	2018-08-22	Novartis AG	Novel formats for organic compounds for use in rna interference
CN112080502A (zh)	2013-10-11	2020-12-15	Ionis制药公司	用于调节c9orf72表达的组合物
US20160230172A1 (en)	2013-10-14	2016-08-11	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of c9orf72 antisense transcript
EP3058069B1 (en)	2013-10-14	2019-07-24	Ionis Pharmaceuticals, Inc.	Methods for modulating expression of c9orf72 antisense transcript
MX2016006106A (es)	2013-11-11	2016-12-09	Sangamo Biosciences Inc	Metodos y composiciones para tratar la enfermedad de huntington.
JP2017501684A (ja)	2013-11-14	2017-01-19	ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅＩｎｎｏｖａｔｉｏｎＣｅｎｔｅｒＣｏｐｅｎｈａｇｅｎＡ／Ｓ	Ａｐｏｂアンチセンスコンジュゲート化合物
US20150167017A1 (en)	2013-12-13	2015-06-18	Moderna Therapeutics, Inc.	Alternative nucleic acid molecules and uses thereof
JPWO2015108048A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
WO2015108047A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108046A1 (ja)	2014-01-15	2017-03-23	株式会社新日本科学	抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
AU2015207773B2 (en)	2014-01-16	2021-06-17	Wave Life Sciences Ltd.	Chiral design
JP6756700B2 (ja)	2014-03-18	2020-09-16	ユニバーシティオブマサチューセッツ	筋萎縮性側索硬化症を処置するためのｒＡＡＶベースの組成物および方法
EP3647318B1 (en)	2014-04-28	2021-06-30	Ionis Pharmaceuticals, Inc.	Linkage modified oligomeric compounds
CN111961669A (zh)	2014-05-01	2020-11-20	Ionis制药公司	用于调节血管生成素样蛋白3表达的组合物和方法
RU2691102C2 (ru)	2014-05-08	2019-06-11	Сангамо Байосайенсиз, Инк.	Способы и композиции для лечения болезни хантингтона
CA2949437C (en)	2014-05-20	2023-08-15	University Of Iowa Research Foundation	Huntington's disease therapeutic compounds
US20160017327A1 (en)	2014-07-11	2016-01-21	The Johns Hopkins University	Phosphorodiamidate morpholino oligomers (pmos) and their use in suppression of mutant huntingtin expression and attenuation of neurotoxicity
CA2955250A1 (en)	2014-07-16	2016-01-21	Moderna Therapeutics, Inc.	Chimeric polynucleotides
EP2982758A1 (en)	2014-08-04	2016-02-10	Centre Hospitalier Universitaire Vaudois (CHUV)	Genome editing for the treatment of huntington's disease
CA2956554C (en)	2014-08-07	2022-03-01	Takeda Pharmaceutical Company Limited	Preparation of cationic lipid compounds and their salts as nucleic acid carriers
WO2016024205A1 (en)	2014-08-15	2016-02-18	Pfizer Inc.	Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
WO2016037191A1 (en)	2014-09-05	2016-03-10	Health Research, Inc.	Use of huntingtin-derived plasmids and peptides for active immunization as a huntington's disease (hd) therapeutic
WO2016079183A1 (en)	2014-11-19	2016-05-26	Roche Innovation Center Copenhagen A/S	Lna chiral phosphorothioates
DK3234131T3 (da)	2014-12-16	2020-06-29	Roche Innovation Ct Copenhagen As	Fremgangsmåde til screening af kiral toksicitet
DK3237618T3 (da)	2014-12-24	2019-06-24	Uniqure Ip Bv	Rnai-induceret huntingtin-genundertrykkelse
US9688707B2 (en)	2014-12-30	2017-06-27	Ionis Pharmaceuticals, Inc.	Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
US10793855B2 (en)	2015-01-06	2020-10-06	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of C9ORF72 antisense transcript
SG11201706293XA (en)	2015-02-04	2017-09-28	Hoffmann La Roche	Tau antisense oligomers and uses thereof
ES2893114T3 (es)	2015-02-04	2022-02-08	Bristol Myers Squibb Co	Métodos para seleccionar moléculas terapéuticas
US20180023081A1 (en)	2015-02-04	2018-01-25	Bristol-Myers Squibb Company	Lna oligonucleotides with alternating flanks
EP3256588A2 (en)	2015-02-10	2017-12-20	Genzyme Corporation	VARIANT RNAi
EP3256587A2 (en)	2015-02-13	2017-12-20	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2016138017A1 (en)	2015-02-23	2016-09-01	Ionis Pharmaceuticals, Inc.	Compounds and methods for increasing antisense activity
US20180036335A1 (en)	2015-03-03	2018-02-08	Ionis Pharmaceuticals, Inc.	Compositions for modulating mecp2 expression
WO2016145142A1 (en)	2015-03-10	2016-09-15	Emory University	Nucleotide and nucleoside therapeutics compositions and uses related thereto
WO2016154096A1 (en)	2015-03-20	2016-09-29	Ionis Pharmaceuticals, Inc.	Modulation of smggds expression
CA2980337A1 (en)	2015-04-03	2016-10-06	University Of Massachusetts	Oligonucleotide compounds for targeting huntingtin mrna
US10851371B2 (en)	2015-04-10	2020-12-01	Ionis Pharmaceuticals, Inc.	Modulation of SMN expression
KR102104163B1 (ko)	2015-04-16	2020-04-23	아이오니스 파마수티컬즈, 인코포레이티드	C9orf72 발현을 조절하기 위한 조성물
US10407678B2 (en)	2015-04-16	2019-09-10	Ionis Pharmaceuticals, Inc.	Compositions for modulating expression of C9ORF72 antisense transcript
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
CA2990699A1 (en)	2015-06-29	2017-01-05	Ionis Pharmaceuticals, Inc.	Modified crispr rna and modified single crispr rna and uses thereof
KR102640776B1 (ko)	2015-07-10	2024-02-23	아이오니스 파마수티컬즈, 인코포레이티드	디아실글리세롤 아실전이효소 2(dgat2) 조절제
WO2017011286A1 (en)	2015-07-10	2017-01-19	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
WO2017015109A1 (en)	2015-07-17	2017-01-26	Alnylam Pharmaceuticals, Inc.	Multi-targeted single entity conjugates
MA43072A (fr)	2015-07-22	2018-05-30	Wave Life Sciences Ltd	Compositions d'oligonucléotides et procédés associés
TW201718620A (zh)	2015-07-27	2017-06-01	阿尼拉製藥公司	黃嘌呤脫氫酶（ＸＤＨ）ｉＲＮＡ組成物及其使用方法
PL3329002T3 (pl)	2015-07-31	2021-04-19	Alnylam Pharmaceuticals, Inc.	Kompozycje irna transtyretyny (ttr) i sposoby ich zastosowania do leczenia lub zapobiegania chorobom związanym z ttr
DK3341479T3 (da)	2015-08-24	2020-02-24	Roche Innovation Ct Copenhagen As	LNA-G-Proces
CN118697894A (zh)	2015-08-25	2024-09-27	阿尔尼拉姆医药品有限公司	用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物
EP3344769B1 (en)	2015-09-02	2024-04-17	Alnylam Pharmaceuticals, Inc.	Programmed cell death 1 ligand 1 (pd-l1) irna compositions and methods of use thereof
US10874686B2 (en)	2015-10-01	2020-12-29	Memorial Sloan-Kettering Cancer Center	Anthranilyl-adenosinemonosulfamate analogs and uses thereof
CA3000709A1 (en)	2015-10-01	2017-04-06	Memorial Sloan-Kettering Cancer Center	Inhibitors of menaquinone biosynthesis
EP3355932B1 (en)	2015-10-02	2023-04-12	Roche Innovation Center Copenhagen A/S	Oligonucleotide conjugation process
CA2999772A1 (en)	2015-10-09	2017-04-13	Wave Life Sciences Ltd.	Oligonucleotide compositions and methods thereof
EP3183347A4 (en)	2015-10-17	2018-04-18	Lifesplice Pharma LLC	Splice modulating oligonucleotides and methods of use thereof
WO2017068087A1 (en)	2015-10-22	2017-04-27	Roche Innovation Center Copenhagen A/S	Oligonucleotide detection method
US10955407B2 (en)	2015-10-22	2021-03-23	Roche Innovation Center Copenhagen A/S	In vitro toxicity screening assay
US11260073B2 (en)	2015-11-02	2022-03-01	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating C90RF72
LT3374509T (lt)	2015-11-12	2021-03-10	F. Hoffmann-La Roche Ag	Oligonukleotidai, skirti sukelti iš tėvo paveldėto ube3a raišką
EP3430019A4 (en)	2016-03-13	2019-10-30	Wave Life Sciences Ltd.	COMPOSITIONS AND METHODS FOR PHOSPHORAMIDITE AND OLIGONUCLEOTIDE SYNTHESIS
PL3430141T3 (pl)	2016-03-14	2022-02-28	F. Hoffmann-La Roche Ag	Oligonukleotydy do obniżenia ekspresji pd-l1
EP3430021A1 (en)	2016-03-18	2019-01-23	Roche Innovation Center Copenhagen A/S	Acyl-protected l-lna-guanosine monomers
WO2017165489A1 (en)	2016-03-23	2017-09-28	Emory University	Antiviral agents for treating zika and dengue virus infections
EP3443094B1 (en)	2016-04-13	2022-10-19	Ionis Pharmaceuticals, Inc.	Methods for reducing c9orf72 expression
WO2017178656A1 (en)	2016-04-14	2017-10-19	Roche Innovation Center Copenhagen A/S	TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
MA45290A (fr)	2016-05-04	2019-03-13	Wave Life Sciences Ltd	Procédés et compositions d'agents biologiquement actifs
US11261209B2 (en)	2016-05-12	2022-03-01	Roche Innovation Center Copenhagen A/S	Enhanced coupling of stereodefined oxazaphospholidine phosphoramidite monomers to nucleoside or oligonucleotide
EP3455354B1 (en)	2016-05-13	2023-07-12	Roche Diagnostics GmbH	Protein-based sample collection matrices and devices
EP3458464A1 (en)	2016-05-18	2019-03-27	ETH Zurich	Stereoselective synthesis of phosphorothioate oligoribonucleotides
MA45188A (fr)	2016-06-03	2019-04-10	Wave Life Sciences Ltd	Oligonucléotides, compositions et méthodes associées
US20190240346A1 (en)	2016-06-20	2019-08-08	Genahead Bio, Inc.	Antibody-drug conjugate
US20190264267A1 (en)	2016-07-25	2019-08-29	Wave Life Sciences Ltd.	Phasing
CN110088113A (zh)	2016-11-23	2019-08-02	波涛生命科学有限公司	用于亚磷酰胺和寡核苷酸合成的组合物和方法

2011
- 2011-09-22 EP EP11826893.7A patent/EP2620428B1/en active Active
- 2011-09-22 US US13/825,627 patent/US10428019B2/en active Active
- 2011-09-22 WO PCT/JP2011/071559 patent/WO2012039448A1/ja active Application Filing
- 2011-09-22 DK DK11826893.7T patent/DK2620428T3/da active
- 2011-09-22 JP JP2012535064A patent/JP5868324B2/ja active Active
2016
- 2016-01-05 JP JP2016000684A patent/JP6450692B2/ja active Active
2018
- 2018-08-21 JP JP2018154836A patent/JP2019006793A/ja active Pending

Also Published As

Publication number	Publication date
US20130178612A1 (en)	2013-07-11
JP2016128431A (ja)	2016-07-14
US10428019B2 (en)	2019-10-01
WO2012039448A1 (ja)	2012-03-29
JPWO2012039448A1 (ja)	2014-02-03
JP2019006793A (ja)	2019-01-17
EP2620428A1 (en)	2013-07-31
JP6450692B2 (ja)	2019-01-09
JP5868324B2 (ja)	2016-02-24
EP2620428A4 (en)	2014-05-21
EP2620428B1 (en)	2019-05-22

Publication	Publication Date	Title
DK2620428T3 (da)	2019-07-01	Asymmetrisk hjælpegruppe
EP2659556A4 (en)	2015-10-21	PRE-CHAMBER IGNITION SYSTEM
EP2578585A4 (en)	2013-10-23	Purinone derivative
DK3225404T3 (da)	2020-02-10	Fluidpatron
DE102011100241A8 (de)	2012-03-01	Nitridhalbleiterbauteil
DK2616465T3 (da)	2016-02-01	Triazin-oxadiazoler
DE10170954T8 (de)	2013-04-25	Mikrowellendruckgarer
DE112011104226A5 (de)	2013-09-26	Käfigmutter
EP2660110A4 (en)	2015-07-22	Wiper blade
DE102011117046A8 (de)	2012-12-27	Doppelkupplungswindungsgetriebe
DE112011102080A5 (de)	2013-04-11	Kupplungszentralausrücker
DE112011101226A5 (de)	2013-01-24	Linearwegmesssystem
DK2442899T3 (da)	2013-10-07	Rotorskive
DK2539163T3 (da)	2015-09-21	Dækventil
DE102011002623A8 (de)	2012-02-02	Ventilsteuerzeitversteller
DE112011102711A5 (de)	2013-05-29	Hydrostataktor
DK2447426T3 (da)	2013-06-03	Vaske-WC
EP2646037A4 (en)	2015-03-18	INHIBITION OF HISTONES
EP2612744A4 (en)	2014-12-17	OPENING CRYSTALLIZATION DEVICE
DE102010038420A8 (de)	2013-01-10	Reinigungungsvorrichtung
DE102010019119B8 (de)	2013-01-31	Cuttermesser
DE112010005518A5 (de)	2013-04-25	Dichtungsmanchette
DE102010035554B8 (de)	2014-12-24	Fußtüröffner
DK2596072T3 (da)	2014-08-11	Bor-forbindelses-suspension
DK2521486T3 (da)	2020-02-03	Palpometer